IB 

Union Calendar No. 596 

115TH CONGRESS 

2D SESSION H. R. 5925 

[Report No. 115–767, Part I] 

To codify provisions relating to the Office of National Drug Control, and 

for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MAY 23, 2018 

Mr. GOWDY (for himself, Mr. CUMMINGS, Mr. MEADOWS, and Mr. CONNOLLY) 

introduced the following bill; which was referred to the Committee on 

Oversight and Government Reform, and in addition to the Committees 

on Energy and Commerce, Foreign Affairs, the Judiciary, Intelligence 

(Permanent Select), and Appropriations, for a period to be subsequently 

determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned 

JUNE 20, 2018 

Reported from the Committee on Oversight and Government Reform with an 

amendment 

[Strike out all after the enacting clause and insert the part printed in italic] 

JUNE 20, 2018 

The Committees on Energy and Commerce, Foreign Affairs, the Judiciary, Intelligence (Permanent Select), and Appropriations discharged; committed 

to the Committee of the Whole House on the State of the Unionand ordered to be printed 

[For text of introduced bill, see copy of bill as introduced on May 23, 2018] 


pbinns on DSK79D2C42PROD with BILLS
2 

•HR 5925 RH

A BILL 

To codify provisions relating to the Office of National Drug 

Control, and for other purposes. 


pbinns on DSK79D2C42PROD with BILLS
3 

•HR 5925 RH

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Coordinated Response 

5 through Interagency Strategy and Information Sharing 

6 Act’’ or the ‘‘CRISIS Act’’. 

7 SEC. 2. OFFICE OF NATIONAL DRUG CONTROL. 

8 (a) REDESIGNATION.—The Office of National Drug 

9 Control Policy shall be known as the ‘‘Office of National 

10 Drug Control’’. 

11 (b) REFERENCES.—Any reference in any other Federal 

12 law, Executive order, rule, regulation, or delegation of au13 thority, or any document of or relating to the Office of Na14 tional Drug Control Policy is deemed to refer to the Office 

15 of National Drug Control. 

16 (c) CODIFICATION.—Subtitle I of title 31, United 

17 States Code, is amended by adding at the end the following 

18 new chapter: 

19 ‘‘CHAPTER 10—OFFICE OF NATIONAL 

20 DRUG CONTROL 

‘‘SUBCHAPTER I—OFFICE

‘‘Sec. 

‘‘1001. Definitions. 

‘‘1002. Office of National Drug Control. 

‘‘1003. Administration of the office. 

‘‘1004. National drug control program budget. 

‘‘1005. National drug control strategy. 

‘‘1006. Development of an annual national drug control assessment. 

‘‘1007. Monitoring and evaluation of national drug control program. 

‘‘1008. Coordination and oversight of the national drug control program. 

‘‘1009. Emerging threats taskforce, plan, media campaign. 


pbinns on DSK79D2C42PROD with BILLS
4 

•HR 5925 RH

‘‘1010. National and international coordination. 

‘‘1011. Interdiction. 

‘‘1012. Treatment coordinator. 

‘‘1013. Critical information coordination. 

‘‘1014. Annual audit and investigation requirements. 

‘‘1015. Authorization of appropriations. 

‘‘SUBCHAPTER II—HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM

‘‘1021. High intensity drug trafficking areas program. 

‘‘SUBCHAPTER III—DRUG-FREE COMMUNITIES SUPPORT PROGRAM

‘‘1031. Establishment of drug-free communities support program. 

‘‘1032. Program authorization. 

‘‘1033. Information collection and dissemination with respect to grant recipients. 

‘‘1034. Technical assistance and training. 

‘‘1035. Supplemental grants for coalition mentoring activities. 

‘‘1036. Authorization for National Community Antidrug Coalition Institute. 

‘‘1037. Definitions. 

‘‘1038. Drug–free communities reauthorization. 

1 ‘‘SUBCHAPTER I—OFFICE 

2 ‘‘§ 1001. Definitions 

3 ‘‘In this chapter: 

4 ‘‘(1) AGENCY.—The term ‘agency’ has the mean5 ing given the term ‘executive agency’ in section 102. 

6 ‘‘(2) APPROPRIATE CONGRESSIONAL COMMIT7 TEES.—The term ‘appropriate congressional commit8 tees’ means— 

9 ‘‘(A) the Committee on the Judiciary, the 

10 Committee on Appropriations, and the Caucus 

11 on International Narcotics Control of the Senate; 

12 and 

13 ‘‘(B) the Committee on Oversight and Gov14 ernment Reform, the Committee on the Judici15 ary, and the Committee on Appropriations of the 

16 House of Representatives. 


pbinns on DSK79D2C42PROD with BILLS
5 

•HR 5925 RH

1 ‘‘(3) DEMAND REDUCTION.—The term ‘demand 

2 reduction’ means any activity conducted by a Na3 tional Drug Control Program Agency, other than an 

4 enforcement activity, that is intended to reduce or 

5 prevent the use of drugs or support or provide treat6 ment and recovery efforts, including— 

7 ‘‘(A) education about the dangers of illicit 

8 drug use; 

9 ‘‘(B) services, programs, or strategies to pre10 vent substance use disorder, including evidence11 based education campaigns, community-based 

12 prevention programs, opioid diversion, collection 

13 and disposal of unused prescription drugs, and 

14 services to at-risk populations to prevent or 

15 delay initial use of an illicit substance; 

16 ‘‘(C) substance use disorder treatment; 

17 ‘‘(D) illicit drug use research; 

18 ‘‘(E) drug-free workplace programs; 

19 ‘‘(F) drug testing, including the testing of 

20 employees; 

21 ‘‘(G) interventions for illicit drug use and 

22 dependence; 

23 ‘‘(H) expanding availability of access to 

24 health care services for the treatment of substance 

25 use disorders; 


pbinns on DSK79D2C42PROD with BILLS
6 

•HR 5925 RH

1 ‘‘(I) international drug control coordination 

2 and cooperation with respect to activities de3 scribed in this paragraph; 

4 ‘‘(J) pre- and post-arrest criminal justice 

5 interventions such as diversion programs, drug 

6 courts, and the provision of evidence-based treat7 ment to individuals with substance use disorders 

8 who are arrested or under some form of criminal 

9 justice supervision, including medication assisted 

10 treatment; 

11 ‘‘(K) other coordinated and joint initiatives 

12 among Federal, State, local, and Tribal agencies 

13 to promote comprehensive drug control strategies 

14 designed to reduce the demand for, and the avail15 ability of, illegal drugs; 

16 ‘‘(L) international illicit drug use edu17 cation, prevention, treatment, recovery, research, 

18 rehabilitation activities, and interventions for il19 licit drug use and dependence; and 

20 ‘‘(M) research related to any of the activi21 ties described in this paragraph. 

22 ‘‘(4) DIRECTOR.—The term ‘Director’ means the 

23 Director of the Office of National Drug Control. 


pbinns on DSK79D2C42PROD with BILLS
7 

•HR 5925 RH

1 ‘‘(5) DRUG.—The term ‘drug’ has the meaning 

2 given the term ‘controlled substance’ in section 102(6) 

3 of the Controlled Substances Act (21 U.S.C. 802(6)). 

4 ‘‘(6) DRUG CONTROL.—The term ‘drug control’ 

5 means any activity conducted by a National Drug 

6 Control Program Agency involving supply reduction 

7 or demand reduction. 

8 ‘‘(7) EMERGING THREAT.—The term ‘emerging 

9 threat’ means the occurrence of a new and growing 

10 trend in the use of an illicit drug or class of drugs, 

11 including rapid expansion in the supply of or de12 mand for such drug. 

13 ‘‘(8) ILLICIT DRUG USE; ILLICIT DRUGS; ILLEGAL

14 DRUGS.—The terms ‘illicit drug use’, ‘illicit drugs’, 

15 and ‘illegal drugs’ include the illegal or illicit use of 

16 prescription drugs. 

17 ‘‘(9) LAW ENFORCEMENT.—The term ‘law en18 forcement’ or ‘drug law enforcement’ means all efforts 

19 by a Federal, State, local, or Tribal government agen20 cy to enforce the drug laws of the United States or 

21 any State, including investigation, arrest, prosecu22 tion, and incarceration or other punishments or pen23 alties. 

24 ‘‘(10) NATIONAL DRUG CONTROL PROGRAM.—The 

25 term ‘National Drug Control Program’ means proVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
8 

•HR 5925 RH

1 grams, policies, and activities undertaken by Na2 tional Drug Control Program Agencies pursuant to 

3 the responsibilities of such agencies under the Na4 tional Drug Control Strategy, including any activi5 ties involving supply reduction, demand reduction, or 

6 State, local, and Tribal affairs. 

7 ‘‘(11) NATIONAL DRUG CONTROL PROGRAM AGEN8 CY.—The term ‘National Drug Control Program 

9 Agency’ means any agency (or bureau, office, inde10 pendent agency, board, division, commission, subdivi11 sion, unit, or other component thereof) that is respon12 sible for implementing any aspect of the National 

13 Drug Control Strategy, including any agency that re14 ceives Federal funds to implement any aspect of the 

15 National Drug Control Strategy, but does not include 

16 any agency that receives funds for drug control activ17 ity solely under the National Intelligence Program or 

18 the Military Intelligence Program. 

19 ‘‘(12) NATIONAL DRUG CONTROL STRATEGY; 

20 STRATEGY.—The term ‘National Drug Control Strat21 egy’ or ‘Strategy’ means the strategy developed and 

22 submitted to Congress under section 1005. 

23 ‘‘(13) NONPROFIT ORGANIZATION.—The term 

24 ‘nonprofit organization’ means an organization that 

25 is described in section 501(c)(3) of the Internal RevVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
9 

•HR 5925 RH

1 enue Code of 1986 and exempt from tax under section 

2 501(a) of such Code. 

3 ‘‘(14) OFFICE.—The term ‘Office’ means the Of4 fice of National Drug Control. 

5 ‘‘(15) STATE, LOCAL, AND TRIBAL AFFAIRS.—The 

6 term ‘State, local, and Tribal affairs’ means domestic 

7 activities conducted by a National Drug Control Pro8 gram Agency that are intended to reduce the avail9 ability and use of illegal drugs, including— 

10 ‘‘(A) coordination and enhancement of Fed11 eral, State, local, and Tribal law enforcement 

12 drug control efforts; 

13 ‘‘(B) coordination and enhancement of ef14 forts among National Drug Control Program 

15 Agencies and State, local, and Tribal demand re16 duction and supply reduction agencies; 

17 ‘‘(C) coordination and enhancement of Fed18 eral, State, local, and Tribal law enforcement 

19 initiatives to gather, analyze, and disseminate 

20 information and law enforcement intelligence re21 lating to drug control among domestic law en22 forcement agencies; and 

23 ‘‘(D) other coordinated and joint initiatives 

24 among Federal, State, local, and Tribal agencies 

25 to promote comprehensive drug control strategies 


pbinns on DSK79D2C42PROD with BILLS
10 

•HR 5925 RH

1 designed to reduce the demand for, and the avail2 ability of, illegal drugs. 

3 ‘‘(16) SUBSTANCE USE DISORDER TREATMENT.— 

4 The term ‘substance use disorder treatment’ means an 

5 evidence-based, professionally directed, deliberate, and 

6 planned regimen including evaluation, observation, 

7 medical monitoring, and rehabilitative services and 

8 interventions such as pharmacotherapy, behavioral 

9 therapy, and individual and group counseling, on an 

10 inpatient or outpatient basis, to help patients with 

11 substance use disorder reach recovery. 

12 ‘‘(17) SUPPLY REDUCTION.—The term ‘supply 

13 reduction’ means any activity or program conducted 

14 by a National Drug Control Program Agency that is 

15 intended to reduce the availability or use of illegal 

16 drugs in the United States or abroad, including— 

17 ‘‘(A) law enforcement outside the United 

18 States; 

19 ‘‘(B) domestic law enforcement; 

20 ‘‘(C) source country programs, including 

21 economic development programs primarily in22 tended to reduce the production or trafficking of 

23 illicit drugs; 


pbinns on DSK79D2C42PROD with BILLS
11 

•HR 5925 RH

1 ‘‘(D) activities to control international traf2 ficking in, and availability of, illegal drugs, in3 cluding— 

4 ‘‘(i) accurate assessment and moni5 toring of international drug production and 

6 interdiction programs and policies; and 

7 ‘‘(ii) coordination and promotion of 

8 compliance with international treaties re9 lating to the production, transportation, or 

10 interdiction of illegal drugs; 

11 ‘‘(E) activities to conduct and promote 

12 international law enforcement programs and 

13 policies to reduce the supply of drugs; 

14 ‘‘(F) activities to facilitate and enhance the 

15 sharing of domestic and foreign intelligence in16 formation among National Drug Control Pro17 gram Agencies, relating to the production and 

18 trafficking of drugs in the United States and in 

19 foreign countries; 

20 ‘‘(G) activities to prevent the diversion of 

21 drugs for their illicit use; and 

22 ‘‘(H) research related to any of the activi23 ties described in this paragraph. 


pbinns on DSK79D2C42PROD with BILLS
12 

•HR 5925 RH

1 ‘‘§ 1002. Office of National Drug Control 

2 ‘‘(a) ESTABLISHMENT OF OFFICE.—There is estab3 lished in the Executive Office of the President an Office of 

4 National Drug Control, which shall— 

5 ‘‘(1) lead national drug control efforts, including 

6 developing and assessing implementation of evidence7 based drug control policy; 

8 ‘‘(2) coordinate and oversee the implementation 

9 of the national drug control policy, including the Na10 tional Drug Control Strategy; 

11 ‘‘(3) assess and certify the adequacy of National 

12 Drug Control Programs and the budget for those pro13 grams; 

14 ‘‘(4) monitor and evaluate the effectiveness of na15 tional drug control policy efforts, including the Na16 tional Drug Control Program Agencies’ programs, by 

17 developing and applying specific goals and perform18 ance measurements and tracking program-level spend19 ing; 

20 ‘‘(5) identify and respond to emerging threats re21 lated to illicit drug use; 

22 ‘‘(6) administer and evaluate grant programs in 

23 furtherance of the National Drug Control Strategy; 

24 and 

25 ‘‘(7) facilitate broad-scale information sharing 

26 and data standardization among Federal, State, and 


pbinns on DSK79D2C42PROD with BILLS
13 

•HR 5925 RH

1 local entities to support the national drug control ef2 forts. 

3 ‘‘(b) DIRECTOR OF NATIONAL DRUG CONTROL AND

4 DEPUTY DIRECTORS.— 

5 ‘‘(1) DIRECTOR.— 

6 ‘‘(A) IN GENERAL.—There shall be at the 

7 head of the Office a Director who shall hold the 

8 same rank and status as the head of an executive 

9 department listed in section 101 of title 5, 

10 United States Code. 

11 ‘‘(B) APPOINTMENT.—The Director shall be 

12 appointed by the President, by and with the ad13 vice and consent of the Senate, and shall serve 

14 at the pleasure of the President. 

15 ‘‘(2) DEPUTY DIRECTOR.— 

16 ‘‘(A) IN GENERAL.—There shall be a Dep17 uty Director who shall report directly to the Di18 rector, be appointed by the President, and serve 

19 at the pleasure of the President. 

20 ‘‘(B) RESPONSIBILITIES.—The Deputy Di21 rector shall— 

22 ‘‘(i) carry out the responsibilities dele23 gated by the Director; and 

24 ‘‘(ii) be responsible for effectively co25 ordinating with the Coordinators. 


pbinns on DSK79D2C42PROD with BILLS
14 

•HR 5925 RH

1 ‘‘(c) RESPONSIBILITIES.— 

2 ‘‘(1) POLICIES, GOALS, OBJECTIVES, AND PRIOR3 ITIES.—The Director shall assist the President in di4 recting national drug control efforts, including estab5 lishing policies, goals, objectives, and priorities for the 

6 National Drug Control Program that are based on 

7 evidence-based research. 

8 ‘‘(2) CONSULTATION.—To formulate the National 

9 Drug Control policies, goals, objectives, and priorities, 

10 the Director— 

11 ‘‘(A) shall consult with— 

12 ‘‘(i) State and local governments; 

13 ‘‘(ii) National Drug Control Program 

14 Agencies; 

15 ‘‘(iii) each committee, working group, 

16 council, or other entity established under 

17 this chapter, as appropriate; 

18 ‘‘(iv) the public; 

19 ‘‘(v) appropriate congressional com20 mittees; and 

21 ‘‘(vi) any other person in the discretion 

22 of the Director; and 

23 ‘‘(B) may— 

24 ‘‘(i) establish advisory councils; 

25 ‘‘(ii) acquire data from agencies; and 


pbinns on DSK79D2C42PROD with BILLS
15 

•HR 5925 RH

1 ‘‘(iii) request data from any other enti2 ty. 

3 ‘‘§ 1003. Administration of the office 

4 ‘‘(a) EMPLOYMENT.— 

5 ‘‘(1) AUTHORITY OF THE DIRECTOR.—The Direc6 tor may select, appoint, employ, and fix compensa7 tion of such officers and employees of the Office as 

8 may be necessary to carry out the functions of the Of9 fice under this chapter. 

10 ‘‘(2) PROHIBITIONS.— 

11 ‘‘(A) GENERALLY.—No person shall serve as 

12 Director or Deputy Director while serving in 

13 any other position in the Federal Government. 

14 ‘‘(B) PROHIBITION ON POLITICAL CAM15 PAIGNING.—Any officer or employee of the Office 

16 who is appointed to that position by the Presi17 dent, by and with the advice and consent of the 

18 Senate, may not participate in Federal election 

19 campaign activities, except that such official is 

20 not prohibited by this paragraph from making 

21 contributions to individual candidates. 

22 ‘‘(b) PROHIBITION ON THE USE OF FUNDS FOR POLIT23 ICAL CAMPAIGNS OR BALLOT INITIATIVES.—No funds au24 thorized under this chapter may be obligated for the purpose 


pbinns on DSK79D2C42PROD with BILLS
16 

•HR 5925 RH

1 of influencing any Federal, State, or local election or ballot 

2 initiative. 

3 ‘‘(c) PERSONNEL DETAILED TO OFFICE.— 

4 ‘‘(1) EVALUATIONS.—Notwithstanding any pro5 vision of chapter 43 of title 5, the Director shall per6 form the evaluation of the performance of any em7 ployee detailed to the Office for purposes of the appli8 cable performance appraisal system established under 

9 such chapter for any rating period, or part thereof, 

10 that such employee is detailed to such office. 

11 ‘‘(2) COMPENSATION.— 

12 ‘‘(A) BONUS PAYMENTS.—Subject to the 

13 availability of appropriations, the Director may 

14 provide periodic bonus payments to any em15 ployee detailed to the Office. 

16 ‘‘(B) RESTRICTIONS.—An amount paid 

17 under this paragraph to an employee for any pe18 riod— 

19 ‘‘(i) shall not be greater than 20 per20 cent of the basic pay paid or payable to 

21 such employee for such period; and 

22 ‘‘(ii) shall be in addition to the basic 

23 pay of such employee. 

24 ‘‘(C) AGGREGATE AMOUNT.—The aggregate 

25 amount paid during any fiscal year to an emVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00016 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
17 

•HR 5925 RH

1 ployee detailed to the Office as basic pay, 

2 awards, bonuses, and other compensation shall 

3 not exceed the annual rate payable at the end of 

4 such fiscal year for positions at level III of the 

5 Executive Schedule. 

6 ‘‘(d) CONGRESSIONAL ACCESS TO INFORMATION.—The 

7 location of the Office in the Executive Office of the President 

8 shall not be construed as affecting access by Congress, or 

9 any committee of the House of Representatives or the Sen10 ate, to any— 

11 ‘‘(1) information, document, or study in the pos12 session of, or conducted by or at the direction of the 

13 Director; or 

14 ‘‘(2) personnel of the Office. 

15 ‘‘(e) OTHER AUTHORITIES OF THE DIRECTOR.—In 

16 carrying out this chapter, the Director may— 

17 ‘‘(1) use for administrative purposes, on a reim18 bursable basis, the available services, equipment, per19 sonnel, and facilities of Federal, State, and local 

20 agencies; 

21 ‘‘(2) procure the services of experts and consult22 ants in accordance with section 3109 of title 5 relat23 ing to appointments in the Federal Service, at rates 

24 of compensation for individuals not to exceed the 

25 daily equivalent of the rate of pay payable under level 


pbinns on DSK79D2C42PROD with BILLS
18 

•HR 5925 RH

1 IV of the Executive Schedule under section 5311 of 

2 such title; and 

3 ‘‘(3) use the mails in the same manner as any 

4 other agency. 

5 ‘‘(f) GENERAL SERVICES ADMINISTRATION.—The Ad6 ministrator of General Services shall provide to the Direc7 tor, on a reimbursable basis, such administrative support 

8 services as the Director may request. 

9 ‘‘§ 1004. National drug control program budget 

10 ‘‘(a) BUDGET RECOMMENDATIONS.—Not later than 

11 July 1 of each year, the Director shall provide to the head 

12 of each National Drug Control Program Agency budget rec13 ommendations, including requests for specific initiatives 

14 that are consistent with the priorities of the President under 

15 the National Drug Control Strategy, which shall— 

16 ‘‘(1) apply to the budget for the next fiscal year 

17 scheduled for formulation under chapter 11, and each 

18 of the 4 subsequent fiscal years; and 

19 ‘‘(2) address funding priorities developed in the 

20 National Drug Control Strategy. 

21 ‘‘(b) RESPONSIBILITIES OF NATIONAL DRUG CONTROL

22 PROGRAM AGENCIES.— 

23 ‘‘(1) IN GENERAL.—For each fiscal year, the 

24 head of each National Drug Control Program Agency 

25 shall transmit to the Director a copy of the proposed 


pbinns on DSK79D2C42PROD with BILLS
19 

•HR 5925 RH

1 drug control budget request of such agency at the 

2 same time as that budget request is submitted to their 

3 superiors (and before submission to the Office of Man4 agement and Budget) in the preparation of the budget 

5 of the President submitted to Congress under section 

6 1105(a). 

7 ‘‘(2) SUBMISSION OF DRUG CONTROL BUDGET

8 REQUESTS.—The head of each National Drug Control 

9 Program Agency shall ensure timely development and 

10 submission to the Director of each proposed drug con11 trol budget request transmitted pursuant to this sub12 section, in such format as may be designated by the 

13 Director with the concurrence of the Director of the 

14 Office of Management and Budget. 

15 ‘‘(3) CONTENT OF DRUG CONTROL BUDGET RE16 QUESTS.—A drug control budget request submitted by 

17 the head of a National Drug Control Program Agency 

18 under this subsection shall include all requests for 

19 funds for any drug control activity undertaken by 

20 such agency, including demand reduction, supply re21 duction, and State, local, and Tribal affairs, includ22 ing any drug law enforcement activities. If an activ23 ity has both drug control and nondrug control pur24 poses or applications, such agency shall estimate by 

25 a documented calculation the total funds requested for 


pbinns on DSK79D2C42PROD with BILLS
20 

•HR 5925 RH

1 that activity that would be used for drug control, and 

2 shall set forth in its request the basis and method for 

3 making the estimate. 

4 ‘‘(c) REVIEW AND CERTIFICATION OF BUDGET RE5 QUESTS AND BUDGET SUBMISSIONS OF NATIONAL DRUG

6 CONTROL PROGRAM AGENCIES.— 

7 ‘‘(1) IN GENERAL.—The Director shall review 

8 each drug control budget request submitted to the Di9 rector under subsection (b). 

10 ‘‘(2) REVIEW OF BUDGET REQUESTS.— 

11 ‘‘(A) INADEQUATE REQUESTS.—If the Di12 rector concludes that a budget request submitted 

13 under subsection (b) is inadequate, in whole or 

14 in part, to implement the objectives of the Na15 tional Drug Control Strategy with respect to the 

16 agency or program at issue for the year for 

17 which the request is submitted, the Director shall 

18 submit to the head of the applicable National 

19 Drug Control Program Agency a written de20 scription identifying the funding levels and spe21 cific initiatives that would, in the determination 

22 of the Director, make the request adequate to im23 plement those objectives. 

24 ‘‘(B) ADEQUATE REQUESTS.—If the Direc25 tor concludes that a budget request submitted 


pbinns on DSK79D2C42PROD with BILLS
21 

•HR 5925 RH

1 under subsection (b) is adequate to implement 

2 the objectives of the National Drug Control 

3 Strategy with respect to the agency or program 

4 at issue for the year for which the request is sub5 mitted, the Director shall submit to the head of 

6 the applicable National Drug Control Program 

7 Agency a written statement confirming the ade8 quacy of the request. 

9 ‘‘(C) RECORD.—The Director shall main10 tain a record of each description submitted 

11 under subparagraph (A) and each statement sub12 mitted under subparagraph (B). 

13 ‘‘(3) SPECIFIC REQUESTS.—The Director shall 

14 not confirm the adequacy of any budget request that 

15 requests a level of funding that will not enable 

16 achievement of the goals of the National Drug Control 

17 Strategy, including— 

18 ‘‘(A) requests funding for Federal law en19 forcement activities that do not adequately com20 pensate for transfers of drug enforcement re21 sources and personnel to law enforcement and 

22 investigation activities; 

23 ‘‘(B) requests funding for law enforcement 

24 activities on the borders of the United States that 


pbinns on DSK79D2C42PROD with BILLS
22 

•HR 5925 RH

1 do not adequately direct resources to drug inter2 diction and enforcement; 

3 ‘‘(C) requests funding for drug treatment 

4 activities that do not provide adequate results 

5 and accountability measures; 

6 ‘‘(D) requests funding for drug treatment 

7 activities that do not adequately support and en8 hance Federal drug treatment programs and ca9 pacity; and 

10 ‘‘(E) requests funding for the operations 

11 and management of the Department of Home12 land Security that does not include a specific re13 quest for funds for the Office of Counternarcotics 

14 Enforcement to carry out its responsibilities 

15 under section 878 of the Homeland Security Act 

16 of 2002 (6 U.S.C. 458). 

17 ‘‘(4) AGENCY RESPONSE.— 

18 ‘‘(A) IN GENERAL.—The head of a National 

19 Drug Control Program Agency that receives a 

20 description under paragraph (2)(A) shall include 

21 the funding levels and initiatives described by 

22 the Director in the budget submission for that 

23 agency to the Office of Management and Budget. 

24 ‘‘(B) IMPACT STATEMENT.—The head of a 

25 National Drug Control Program Agency that has 


pbinns on DSK79D2C42PROD with BILLS
23 

•HR 5925 RH

1 altered its budget submission under this para2 graph shall include as an appendix to the budget 

3 submission for that agency to the Office of Man4 agement and Budget an impact statement that 

5 summarizes— 

6 ‘‘(i) the changes made to the budget 

7 under this paragraph; and 

8 ‘‘(ii) the impact of those changes on the 

9 ability of that agency to perform its other 

10 responsibilities, including any impact on 

11 specific missions or programs of the agency. 

12 ‘‘(C) CONGRESSIONAL NOTIFICATION.—The 

13 head of a National Drug Control Program Agen14 cy shall submit a copy of any impact statement 

15 under subparagraph (B) to the Senate, the 

16 House of Representatives, and the appropriate 

17 congressional committees, at the time the budget 

18 for that agency is submitted to Congress under 

19 section 1105(a). 

20 ‘‘(5) CERTIFICATION OF BUDGET SUBMIS21 SIONS.— 

22 ‘‘(A) IN GENERAL.—At the time a National 

23 Drug Control Program Agency submits its budg24 et request to the Office of Management and 

25 Budget, the head of the National Drug Control 


pbinns on DSK79D2C42PROD with BILLS
24 

•HR 5925 RH

1 Program Agency shall submit a copy of the 

2 budget request to the Director. 

3 ‘‘(B) REVIEW AND CERTIFICATION OF SUB4 MISSIONS.—The Director shall review each budg5 et submission submitted under subparagraph (A) 

6 and submit to the appropriate congressional 

7 committees one of the following: 

8 ‘‘(i) A written certification of the budg9 et request for the agency indicating such re10 quest fully funds the National Drug Control 

11 Programs as necessary to achieve the goals 

12 of the National Drug Control Strategy, in13 cluding a written statement explaining the 

14 basis for the determination that the budget 

15 provides sufficient resources for the agency 

16 to achieve the goals of the Strategy. 

17 ‘‘(ii) A written certification of the 

18 budget request for the agency indicating 

19 such request partially funds the National 

20 Drug Control Programs as necessary to 

21 achieve the goals of the Strategy, including 

22 a written statement explaining the basis for 

23 the determination and identifying the level 

24 of funding sufficient to achieve the goals of 

25 the Strategy. 


pbinns on DSK79D2C42PROD with BILLS
25 

•HR 5925 RH

1 ‘‘(iii) A written decertification of the 

2 budget request for the agency indicating the 

3 Director is unable to determine whether 

4 such budget request for the agency fully 

5 funds or partially funds the National Drug 

6 Control Programs as necessary to achieve 

7 the goals of the National Drug Control 

8 Strategy, including a written statement 

9 identifying the additional information nec10 essary for the Director to make a deter11 mination on such budget and the level of 

12 funding sufficient to achieve the goals of the 

13 Strategy. 

14 ‘‘(iv) A written decertification of the 

15 budget request for the agency indicating 

16 that such budget is insufficient to fund the 

17 National Drug Control Programs as nec18 essary to achieve the goals of the Strategy, 

19 including a written statement explaining 

20 the basis for the determination that the 

21 budget is insufficient and identifying the 

22 level of funding sufficient to achieve the 

23 goals of the Strategy. 

24 ‘‘(d) NATIONAL DRUG CONTROL PROGRAM BUDGET

25 PROPOSAL.—For each fiscal year, following the transVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00025 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
26 

•HR 5925 RH

1 mission of proposed drug control budget requests to the Di2 rector under subsection (b), the Director shall, in consulta3 tion with the head of each National Drug Control Program 

4 Agency and the head of each major national organization 

5 that represents law enforcement officers, agencies, or asso6 ciations— 

7 ‘‘(1) develop a consolidated National Drug Con8 trol Program budget proposal designed to implement 

9 the National Drug Control Strategy and to inform 

10 Congress and the public about the total amount pro11 posed to be spent on all supply reduction, demand re12 duction, State, local, and Tribal affairs, including 

13 any drug law enforcement, and other drug control ac14 tivities by the Federal Government, which shall con15 form to the content requirements set forth in sub16 section (b)(3) and include— 

17 ‘‘(A) for each National Drug Control Pro18 gram Agency, a list of whether the funding level 

19 is full, partial, or insufficient to achieve the 

20 goals of the National Drug Control Strategy or 

21 whether the Director is unable to determine 

22 whether the budget request for the agency fully 

23 funds or partially funds the agency’s activities 

24 and contributions as necessary to achieve the 

25 goals of National Drug Control Strategy; 


pbinns on DSK79D2C42PROD with BILLS
27 

•HR 5925 RH

1 ‘‘(B) a statement describing the extent to 

2 which any budget of a National Drug Control 

3 Program Agency with less than full funding 

4 hinders progress on achieving the goals of the 

5 National Drug Control Strategy; and 

6 ‘‘(C) alternative funding structures that 

7 could improve progress on achieving the goals of 

8 the National Drug Control Strategy; and 

9 ‘‘(2) submit the consolidated budget proposal to 

10 the President and Congress. 

11 ‘‘(e) BUDGET ESTIMATE OR REQUEST SUBMISSION TO

12 CONGRESS.—Whenever the Director submits any budget es13 timate or request to the President or the Office of Manage14 ment and Budget, the Director shall concurrently transmit 

15 copies of that estimate or request to the appropriate congres16 sional committees. 

17 ‘‘(f) REPROGRAMMING AND TRANSFER REQUESTS.— 

18 ‘‘(1) IN GENERAL.—No National Drug Control 

19 Program Agency shall submit to Congress a re20 programming or transfer request with respect to any 

21 amount of appropriated funds in an amount exceed22 ing $1,000,000 that is included in the National Drug 

23 Control Program budget unless the request has been 

24 approved by the Director. If the Director has not re25 sponded to a request for reprogramming subject to 


pbinns on DSK79D2C42PROD with BILLS
28 

•HR 5925 RH

1 this paragraph within 30 days after receiving notice 

2 of the request having been made, the request shall be 

3 deemed approved by the Director under this para4 graph and forwarded to Congress. 

5 ‘‘(2) APPEAL.—The head of any National Drug 

6 Control Program Agency may appeal to the President 

7 any disapproval by the Director of a reprogramming 

8 or transfer request under this subsection. 

9 ‘‘§ 1005. National drug control strategy 

10 ‘‘(a) IN GENERAL.— 

11 ‘‘(1) STATEMENT OF DRUG POLICY PRIOR12 ITIES.—The Director shall release a statement of drug 

13 policy priorities in the calendar year of a Presi14 dential inauguration following the inauguration but 

15 not later than April 1. 

16 ‘‘(2) NATIONAL DRUG CONTROL STRATEGY SUB17 MITTED BY THE PRESIDENT.—Not later than the first 

18 Monday in February following the year in which the 

19 term of the President commences, the President shall 

20 submit to Congress a National Drug Control Strat21 egy. 

22 ‘‘(b) DEVELOPMENT OF THE NATIONAL DRUG CON23 TROL STRATEGY.— 

24 ‘‘(1) PROMULGATION.—The Director shall pro25 mulgate the National Drug Control Strategy, which 


pbinns on DSK79D2C42PROD with BILLS
29 

•HR 5925 RH

1 shall set forth a comprehensive plan to reduce illicit 

2 drug use and the consequences of such illicit drug use 

3 in the United States by limiting the availability of 

4 and reducing the demand for illegal drugs and pro5 moting prevention, early intervention, treatment, and 

6 recovery support for individuals with substance use 

7 disorders. 

8 ‘‘(2) STATE AND LOCAL COMMITMENT.—The Di9 rector shall seek the support and commitment of 

10 State, local, and Tribal officials in the formulation 

11 and implementation of the National Drug Control 

12 Strategy. 

13 ‘‘(3) STRATEGY BASED ON EVIDENCE.—The Di14 rector shall ensure the National Drug Control Strat15 egy is based on the best available medical and sci16 entific evidence regarding the policies that are most 

17 effective in reducing the demand for and supply of il18 legal drugs. 

19 ‘‘(4) PROCESS FOR DEVELOPMENT AND SUBMIS20 SION OF NATIONAL DRUG CONTROL STRATEGY.—In 

21 developing and effectively implementing the National 

22 Drug Control Strategy, the Director— 

23 ‘‘(A) shall consult with— 

24 ‘‘(i) the heads of the National Drug 

25 Control Program Agencies; 


pbinns on DSK79D2C42PROD with BILLS
30 

•HR 5925 RH

1 ‘‘(ii) the United States Interdiction 

2 Coordinator; 

3 ‘‘(iii) the Interdiction Committee; 

4 ‘‘(iv) the appropriate congressional 

5 committees and any other committee of ju6 risdiction; 

7 ‘‘(v) State, local, and Tribal officials; 

8 ‘‘(vi) private citizens and organiza9 tions, including community and faith-based 

10 organizations, with experience and expertise 

11 in demand reduction; 

12 ‘‘(vii) private citizens and organiza13 tions with experience and expertise in sup14 ply reduction; and 

15 ‘‘(viii) appropriate representatives of 

16 foreign governments; and 

17 ‘‘(B) in satisfying the requirements of sub18 paragraph (A), shall ensure, to the maximum ex19 tent possible, that State, local, and Tribal offi20 cials and relevant private organizations commit 

21 to support and take steps to achieve the goals 

22 and objectives of the National Drug Control 

23 Strategy. 

24 ‘‘(c) CONTENTS OF THE NATIONAL DRUG CONTROL

25 STRATEGY.— 


pbinns on DSK79D2C42PROD with BILLS
31 

•HR 5925 RH

1 ‘‘(1) IN GENERAL.—The National Drug Control 

2 Strategy submitted under subsection (a)(2) shall in3 clude the following: 

4 ‘‘(A) A description of the current prevalence 

5 of illicit drug use in the United States, including 

6 both the availability of illicit drugs and the 

7 prevalence of substance use disorders, which shall 

8 include the following: 

9 ‘‘(i) Such description for the previous 

10 three years for any drug identified as an 

11 emerging threat under section 1009 and 

12 any other illicit drug identified by the Di13 rector as having a significant impact on the 

14 prevalence of illicit drug use. 

15 ‘‘(ii) A summary of the data and 

16 trends presented in the Drug Control Data 

17 Dashboard required under section 1013. 

18 ‘‘(B) A mission statement detailing the 

19 major functions of the National Drug Control 

20 Program. 

21 ‘‘(C) A list of comprehensive, research-based, 

22 long-range, quantifiable goals for reducing illicit 

23 drug use, including— 


pbinns on DSK79D2C42PROD with BILLS
32 

•HR 5925 RH

1 ‘‘(i) the percentage of the total flow of 

2 illicit drugs to be interdicted during the 

3 time period covered by the Strategy; and 

4 ‘‘(ii) the number of individuals to re5 ceive treatment for substance use disorders. 

6 ‘‘(D) A description of how each goal listed 

7 in the National Drug Control Strategy will be 

8 achieved, including— 

9 ‘‘(i) a list of relevant National Drug 

10 Control Program Agencies and each such 

11 agency’s related programs, activities, and 

12 available assets and the role of each such 

13 program, activity, and asset in achieving 

14 the goal; 

15 ‘‘(ii) a list of relevant stakeholders and 

16 each such stakeholder’s role in achieving the 

17 goal; 

18 ‘‘(iii) an estimate of Federal funding 

19 and other resources needed to achieve each 

20 goal; 

21 ‘‘(iv) an identification of existing or 

22 new coordinating mechanisms needed to 

23 achieve the goal; and 

24 ‘‘(v) a description of the Office’s role in 

25 facilitating the achievement of such goal. 


pbinns on DSK79D2C42PROD with BILLS
33 

•HR 5925 RH

1 ‘‘(E) For each year covered by the Strategy, 

2 a performance evaluation plan for each goal list3 ed in the National Drug Control Strategy for 

4 each National Drug Control Program Agency, 

5 including— 

6 ‘‘(i) specific performance measures for 

7 each National Drug Control Program Agen8 cy and each such agency’s related programs 

9 and activities; 

10 ‘‘(ii) annual and quarterly objectives 

11 and targets for each performance measure; 

12 and 

13 ‘‘(iii) an estimate of Federal funding 

14 and other resources needed to achieve each 

15 performance measure. 

16 ‘‘(F) A list identifying existing data sources 

17 or a description of data collection needed to 

18 evaluate performance, including a description of 

19 how the Director will obtain such data. 

20 ‘‘(G) A list of anticipated challenges to 

21 achieving the National Drug Control Strategy 

22 goals and planned actions to address such chal23 lenges; 

24 ‘‘(H) A description of how each goal was de25 termined, including— 


pbinns on DSK79D2C42PROD with BILLS
34 

•HR 5925 RH

1 ‘‘(i) a description of each required con2 sultation and how such consultation was in3 corporated; 

4 ‘‘(ii) data, research, or other informa5 tion used to inform the decision; and 

6 ‘‘(iii) a statement of whether the goal 

7 established in subparagraph (C)(i) will be 

8 adequate to disrupt drug trafficking organi9 zations that supply the majority of foreign10 sourced illicit drugs trafficked into the 

11 United States. 

12 ‘‘(I) A 5-year projection for program and 

13 budget priorities. 

14 ‘‘(J) A review of international, State, local, 

15 and private sector drug control activities to en16 sure that the United States pursues coordinated 

17 and effective drug control at all levels of govern18 ment. 

19 ‘‘(K) Such statistical data and information 

20 as the Director considers appropriate to dem21 onstrate and assess trends relating to illicit drug 

22 use, the effects and consequences of illicit drug 

23 use (including the effects on children), supply re24 duction, demand reduction, drug-related law enVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00034 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
35 

•HR 5925 RH

1 forcement, and the implementation of the Na2 tional Drug Control Strategy. 

3 ‘‘(2) ADDITIONAL STRATEGIES.— 

4 ‘‘(A) IN GENERAL.—The Director shall in5 clude in the National Drug Control Strategy the 

6 additional strategies required under this para7 graph and shall comply with the following: 

8 ‘‘(i) Provide a copy of the additional 

9 strategies to the appropriate congressional 

10 committees and to the Committee on Armed 

11 Services and the Committee on Homeland 

12 Security of the House of Representatives, 

13 and the Committee on Homeland Security 

14 and Governmental Affairs and the Com15 mittee on Armed Services of the Senate. 

16 ‘‘(ii) Issue the additional strategies in 

17 consultation with the head of each relevant 

18 National Drug Control Program Agency 

19 and any relevant official of a State, local or 

20 Tribal government, and the government of 

21 other countries. 

22 ‘‘(iii) Not change any existing agency 

23 authority or construe any strategy described 

24 under this paragraph to amend or modify 

25 any law governing interagency relationship 


pbinns on DSK79D2C42PROD with BILLS
36 

•HR 5925 RH

1 but may include recommendations about 

2 changes to such authority or law. 

3 ‘‘(iv) Present separately from the rest 

4 of any strategy described under this para5 graph any information classified under cri6 teria established by an Executive order, or 

7 whose public disclosure, as determined by 

8 the Director or the head of any relevant Na9 tional Drug Control Program Agency, 

10 would be detrimental to the law enforcement 

11 or national security activities of any Fed12 eral, State, local, or Tribal agency. 

13 ‘‘(B) REQUIREMENT FOR SOUTHWEST BOR14 DER COUNTERNARCOTICS.— 

15 ‘‘(i) PURPOSES.—The Southwest Bor16 der Counternarcotics Strategy shall— 

17 ‘‘(I) set forth the Government’s 

18 strategy for preventing the illegal traf19 ficking of drugs across the inter20 national border between the United 

21 States and Mexico, including through 

22 ports of entry and between ports of 

23 entry on that border; 

24 ‘‘(II) state the specific roles and 

25 responsibilities of the relevant National 


pbinns on DSK79D2C42PROD with BILLS
37 

•HR 5925 RH

1 Drug Control Program Agencies for 

2 implementing that strategy; and 

3 ‘‘(III) identify the specific re4 sources required to enable the relevant 

5 National Drug Control Program Agen6 cies to implement that strategy. 

7 ‘‘(ii) SPECIFIC CONTENT RELATED TO

8 DRUG TUNNELS BETWEEN THE UNITED

9 STATES AND MEXICO.—The Southwest Bor10 der Counternarcotics Strategy shall in11 clude— 

12 ‘‘(I) a strategy to end the con13 struction and use of tunnels and sub14 terranean passages that cross the inter15 national border between the United 

16 States and Mexico for the purpose of il17 legal trafficking of drugs across such 

18 border; and 

19 ‘‘(II) recommendations for crimi20 nal penalties for persons who construct 

21 or use such a tunnel or subterranean 

22 passage for such a purpose. 

23 ‘‘(C) REQUIREMENT FOR NORTHERN BOR24 DER COUNTERNARCOTICS STRATEGY.— 


pbinns on DSK79D2C42PROD with BILLS
38 

•HR 5925 RH

1 ‘‘(i) PURPOSES.—The Northern Border 

2 Counternarcotics Strategy shall— 

3 ‘‘(I) set forth the strategy of the 

4 Federal Government for preventing the 

5 illegal trafficking of drugs across the 

6 international border between the 

7 United States and Canada, including 

8 through ports of entry and between 

9 ports of entry on the border; 

10 ‘‘(II) state the specific roles and 

11 responsibilities of each relevant Na12 tional Drug Control Program Agency 

13 for implementing the strategy; 

14 ‘‘(III) identify the specific re15 sources required to enable the relevant 

16 National Drug Control Program Agen17 cies to implement the strategy; 

18 ‘‘(IV) be designed to promote, and 

19 not hinder, legitimate trade and travel; 

20 and 

21 ‘‘(V) reflect the unique nature of 

22 small communities along the inter23 national border between the United 

24 States and Canada, ongoing coopera25 tion and coordination with Canadian 


pbinns on DSK79D2C42PROD with BILLS
39 

•HR 5925 RH

1 law, enforcement authorities, and vari2 ations in the volumes of vehicles and 

3 pedestrians crossing through ports of 

4 entry along the international border 

5 between the United States and Canada. 

6 ‘‘(ii) SPECIFIC CONTENT RELATED TO

7 CROSS-BORDER INDIAN RESERVATIONS.— 

8 The Northern Border Counternarcotics 

9 Strategy shall include— 

10 ‘‘(I) a strategy to end the illegal 

11 trafficking of drugs to or through In12 dian reservations on or near the inter13 national border between the United 

14 States and Canada; and 

15 ‘‘(II) recommendations for addi16 tional assistance, if any, needed by 

17 Tribal law enforcement agencies relat18 ing to the strategy, including an eval19 uation of Federal technical and finan20 cial assistance, infrastructure capacity 

21 building, and interoperability defi22 ciencies. 

23 ‘‘(3) CLASSIFIED INFORMATION.—Any contents 

24 of the National Drug Control Strategy that involve 

25 information properly classified under criteria estabVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00039 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
40 

•HR 5925 RH

1 lished by an Executive order shall be presented to 

2 Congress separately from the rest of the National 

3 Drug Control Strategy. 

4 ‘‘(4) SELECTION OF DATA AND INFORMATION.— 

5 In selecting data and information for inclusion under 

6 paragraph (1), the Director shall ensure— 

7 ‘‘(A) the inclusion of data and information 

8 that will permit analysis of current trends 

9 against previously compiled data and informa10 tion where the Director believes such analysis en11 hances long-term assessment of the National 

12 Drug Control Strategy; and 

13 ‘‘(B) the inclusion of data and information 

14 to permit a standardized and uniform assess15 ment of the effectiveness of drug treatment pro16 grams in the United States. 

17 ‘‘(d) ANNUAL PERFORMANCE SUPPLEMENT.—Not later 

18 than the first Monday in February of each year following 

19 the year in which the National Drug Control Strategy is 

20 submitted pursuant to subsection (a)(2), the Director shall 

21 submit to the appropriate congressional committees a sup22 plement to the Strategy that shall include— 

23 ‘‘(1) annual and quarterly quantifiable and 

24 measurable objectives and specific targets to accomVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00040 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
41 

•HR 5925 RH

1 plish long-term quantifiable goals specified in the 

2 Strategy; and 

3 ‘‘(2) for each year covered by the Strategy, a per4 formance evaluation plan for each goal listed in the 

5 Strategy for each National Drug Control Program 

6 Agency, including— 

7 ‘‘(A) specific performance measures for each 

8 National Drug Control Program Agency and 

9 each such agency’s related programs and activi10 ties; 

11 ‘‘(B) annual and quarterly objectives and 

12 targets for each performance measure; and 

13 ‘‘(C) an estimate of Federal funding and 

14 other resources needed to achieve each perform15 ance measure. 

16 ‘‘(e) SUBMISSION OF REVISED STRATEGY.—The Presi17 dent may submit to Congress a revised National Drug Con18 trol Strategy that meets the requirements of this section— 

19 ‘‘(1) at any time, upon a determination of the 

20 President, in consultation with the Director, that the 

21 National Drug Control Strategy in effect is not suffi22 ciently effective; or 

23 ‘‘(2) if a new President or Director takes office. 

24 ‘‘(f) FAILURE OF PRESIDENT TO SUBMIT NATIONAL

25 DRUG CONTROL STRATEGY.—If the President does not subVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00041 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
42 

•HR 5925 RH

1 mit a National Drug Control Strategy to Congress in ac2 cordance with subsection (a)(2), not later than five days 

3 after the first Monday in February following the year in 

4 which the term of the President commences, the President 

5 shall send a notification to the appropriate congressional 

6 committees— 

7 ‘‘(1) explaining why the Strategy was not sub8 mitted; and 

9 ‘‘(2) specifying the date by which the Strategy 

10 will be submitted. 

11 ‘‘§ 1006. Development of an annual national drug con12 trol assessment 

13 ‘‘(a) TIMING.—Not later than the first Monday in Feb14 ruary of each year, the Director shall submit to the Presi15 dent, Congress, and the appropriate congressional commit16 tees, a report assessing the progress of each National Drug 

17 Control Program Agency toward achieving the annual 

18 goals, objectives, and targets contained in the National 

19 Drug Control Strategy applicable to the prior fiscal year. 

20 ‘‘(b) PROCESS FOR DEVELOPMENT OF THE ANNUAL

21 ASSESSMENT.—Not later than November 1 of each year, the 

22 head of each National Drug Control Program Agency shall 

23 submit, in accordance with guidance issued by the Director, 

24 to the Director an evaluation of progress by the agency with 

25 respect to drug control program goals using the performance 


pbinns on DSK79D2C42PROD with BILLS
43 

•HR 5925 RH

1 measures for the agency developed under this section, in2 cluding progress with respect to— 

3 ‘‘(1) success in achieving the goals of the Na4 tional Drug Control Strategy; 

5 ‘‘(2) success in reducing domestic and foreign 

6 sources of illegal drugs; 

7 ‘‘(3) success in expanding access to and increas8 ing the effectiveness of substance use disorder treat9 ment; 

10 ‘‘(4) success in protecting the borders of the 

11 United States (and in particular the Southwestern 

12 border of the United States) from penetration by ille13 gal narcotics; 

14 ‘‘(5) success in reducing crime associated with 

15 drug use in the United States; 

16 ‘‘(6) success in reducing the negative health and 

17 social consequences of drug use in the United States; 

18 and 

19 ‘‘(7) implementation of drug treatment and pre20 vention programs in the United States and improve21 ments in the adequacy and effectiveness of such pro22 grams. 

23 ‘‘(c) CONTENTS OF THE ANNUAL ASSESSMENT.—The 

24 Director shall include in the annual assessment required 

25 under subsection (a)— 


pbinns on DSK79D2C42PROD with BILLS
44 

•HR 5925 RH

1 ‘‘(1) a summary of each evaluation received by 

2 the Director under subsection (b); 

3 ‘‘(2) a summary of the progress of each National 

4 Drug Control Program Agency toward the drug con5 trol program goals of the agency using the perform6 ance measures for the agency developed under this sec7 tion; 

8 ‘‘(3) an assessment of the effectiveness of each 

9 Drug Control Program agency and program in 

10 achieving the National Drug Control Strategy for the 

11 previous year, including a specific evaluation of 

12 whether the applicable goals, measures, objectives, and 

13 targets for the previous year were met; 

14 ‘‘(4) for National Drug Control Program Agen15 cies that administer grant programs, an evaluation of 

16 the effectiveness of each grant program, including an 

17 accounting of the funds disbursed by the program in 

18 the prior year and a summary of how those funds 

19 were used by the grantees and sub-grantees during 

20 that period; 

21 ‘‘(5) a detailed accounting of the amount of 

22 funds obligated by each National Drug Control Pro23 gram Agency in carrying out the responsibilities of 

24 that agency under the Strategy, including the inforVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00044 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
45 

•HR 5925 RH

1 mation submitted to the Director under section 

2 1007(b); 

3 ‘‘(6) an assessment of the effectiveness of any 

4 Emerging Threat Response Plan in effect for the pre5 vious year, including a specific evaluation of whether 

6 the objectives and targets were met and reasons for the 

7 success or failure of the previous year’s plan; 

8 ‘‘(7) a detailed accounting of the amount of 

9 funds obligated during the previous fiscal year for 

10 carrying out the media campaign under section 

11 1009(d), including each recipient of funds, the pur12 pose of each expenditure, the amount of each expendi13 ture, any available outcome information, and any 

14 other information necessary to provide a complete ac15 counting of the funds expended; and 

16 ‘‘(8) the assessments required under this sub17 section shall be based on the Performance Measure18 ment System describe in subsection (d). 

19 ‘‘(d) PERFORMANCE MEASUREMENT SYSTEM.—The 

20 Director shall include in the annual assessment required 

21 under subsection (a) a national drug control performance 

22 measurement system, that— 

23 ‘‘(1) develops annual, 2-year, and 5-year per24 formance measures, objectives, and targets for each 

25 National Drug Control Strategy goal and objective esVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00045 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
46 

•HR 5925 RH

1 tablished for reducing drug use, availability, and the 

2 consequences of drug use; 

3 ‘‘(2) describes the sources of information and 

4 data that will be used for each performance measure 

5 incorporated into the performance measurement sys6 tem; 

7 ‘‘(3) identifies major programs and activities of 

8 the National Drug Control Program Agencies that 

9 support the goals and annual objectives of the Na10 tional Drug Control Strategy; 

11 ‘‘(4) evaluates the contribution of demand reduc12 tion and supply reduction activities implemented by 

13 each National Drug Control Program Agency in sup14 port of the National Drug Control Strategy; 

15 ‘‘(5) monitors consistency between the drug-re16 lated goals, measures, targets, and objectives of the 

17 National Drug Control Program Agencies and ensures 

18 that each agency’s goals and budgets support, and are 

19 fully consistent with, the National Drug Control 

20 Strategy; and 

21 ‘‘(6) coordinates the development and implemen22 tation of national drug control data collection and re23 porting systems to support policy formulation and 

24 performance measurement, including an assessment 

25 of— 


pbinns on DSK79D2C42PROD with BILLS
47 

•HR 5925 RH

1 ‘‘(A) the quality of current drug use meas2 urement instruments and techniques to measure 

3 supply reduction and demand reduction activi4 ties; 

5 ‘‘(B) the adequacy of the coverage of exist6 ing national drug use measurement instruments 

7 and techniques to measure the illicit drug user 

8 population, and groups that are at risk for illicit 

9 drug use; 

10 ‘‘(C) the adequacy of the coverage of existing 

11 national treatment outcome monitoring systems 

12 to measure the effectiveness of substance use dis13 order treatment in reducing illicit drug use and 

14 criminal behavior during and after the comple15 tion of substance use disorder treatment; and 

16 ‘‘(D) the actions the Director shall take to 

17 correct any deficiencies and limitations identi18 fied pursuant to subparagraphs (A), (B), and 

19 (C). 

20 ‘‘(e) MODIFICATIONS.—A description of any modifica21 tions made during the preceding year to the national drug 

22 performance measurement system described in subsection 

23 (d) shall be included in each report submitted under sub24 section (a). 


pbinns on DSK79D2C42PROD with BILLS
48 

•HR 5925 RH

1 ‘‘(f) ANNUAL REPORT ON CONSULTATION.—The Direc2 tor shall include in the annual assessment required under 

3 subsection (a)— 

4 ‘‘(1) a detailed description of how the Office has 

5 consulted with and assisted State, local, and Tribal 

6 governments with respect to the formulation and im7 plementation of the National Drug Control Strategy 

8 and other relevant issues; and 

9 ‘‘(2) a general review of the status of, and trends 

10 in, demand reduction activities by private sector enti11 ties and community-based organizations, including 

12 faith-based organizations, to determine their effective13 ness and the extent of cooperation, coordination, and 

14 mutual support between such entities and organiza15 tions and Federal, State, local, and Tribal govern16 ment agencies. 

17 ‘‘(g) PERFORMANCE-BUDGET COORDINATOR.— 

18 ‘‘(1) DESIGNATION.—The Director shall des19 ignate or appoint a United States Performance-Budg20 et Coordinator to— 

21 ‘‘(A) ensure the Director has sufficient in22 formation about the performance of each Na23 tional Drug Control Program Agency, the im24 pact Federal funding has had on the goals in the 

25 Strategy, and the likely contributions to the 


pbinns on DSK79D2C42PROD with BILLS
49 

•HR 5925 RH

1 goals of the Strategy based on funding levels of 

2 each National Drug Control Program Agency, to 

3 make an independent assessment of the budget 

4 request of each agency under section 1004; 

5 ‘‘(B) advise the Director on agency budgets, 

6 performance measures and targets, and addi7 tional data and research needed to make in8 formed policy decisions in the National Drug 

9 Control Budget and Strategy; and 

10 ‘‘(C) other duties as may be determined by 

11 the Director with respect to measuring or assess12 ing performance or agency budgets. 

13 ‘‘(2) DETERMINATION OF POSITION.—The Direc14 tor shall determine whether the coordinator position 

15 is a career or noncareer position in the Senior Execu16 tive Service. 

17 ‘‘§ 1007. Monitoring and evaluation of national drug 

18 control program 

19 ‘‘(a) IN GENERAL.—The Director shall monitor imple20 mentation of the National Drug Control Program and the 

21 activities of the National Drug Control Program Agencies 

22 in carrying out the goals and objectives of the National 

23 Drug Control Strategy including— 

24 ‘‘(1) conducting program and performance au25 dits and evaluations; and 


pbinns on DSK79D2C42PROD with BILLS
50 

•HR 5925 RH

1 ‘‘(2) requesting assistance from the Inspector 

2 General of the relevant agency in such audits and 

3 evaluations. 

4 ‘‘(b) ACCOUNTING OF FUNDS EXPENDED.—Not later 

5 than December 1 of each year and in accordance with guid6 ance issued by the Director, the head of each National Drug 

7 Control Program Agency shall submit to the Director a de8 tailed accounting of all funds expended by the agency for 

9 National Drug Control Program activities during the pre10 vious fiscal year and shall ensure such detailed accounting 

11 is authenticated by the Inspector General for such agency 

12 prior to submission to the Director. 

13 ‘‘(c) NOTIFICATION.—The Director shall notify any 

14 National Drug Control Program Agency if its activities are 

15 not in compliance with the responsibilities of the agency 

16 under the National Drug Control Strategy, transmit a copy 

17 of each such notification to the President and the appro18 priate congressional committees, and maintain a copy of 

19 each such notification. 

20 ‘‘(d) RECOMMENDATIONS.—The Director shall make 

21 such recommendations to the President and the appropriate 

22 congressional committees as the Director determines are ap23 propriate regarding changes in the organization, manage24 ment, and budgets of the National Drug Control Program 

25 Agencies, and changes in the allocation of personnel to and 


pbinns on DSK79D2C42PROD with BILLS
51 

•HR 5925 RH

1 within those agencies, to implement the policies, goals, pri2 orities, and objectives established under section 1002(c)(1) 

3 and the National Drug Control Strategy. 

4 ‘‘(e) AUTHORIZATION, DEVELOPMENT, AND IMPLEMEN5 TATION OF A COORDINATED TRACKING SYSTEM.— 

6 ‘‘(1) ESTABLISHMENT.—The Director, shall es7 tablish a coordinated tracking system of federally8 funded initiatives and grant programs which shall— 

9 ‘‘(A) be the central repository of all relevant 

10 grants; 

11 ‘‘(B) identify duplication, overlap, or gaps 

12 in funding to provide increased accountability of 

13 federally-funded grants for substance abuse treat14 ment, prevention, and enforcement; 

15 ‘‘(C) identify impediments that applicants 

16 currently have in the grant application process 

17 with applicable agencies; and 

18 ‘‘(D) be developed and maintained by the 

19 Office with the support of designated National 

20 Drug Control Program Agencies, and any other 

21 agency determined by the Director. 

22 ‘‘(2) PERFORMANCE METRICS.—The Director 

23 shall identify metrics and achievable goals for grant 

24 recipients in furtherance of the Strategy. Such 

25 metrics should be used to measure how effective each 


pbinns on DSK79D2C42PROD with BILLS
52 

•HR 5925 RH

1 federally funded initiative is in achieving the objec2 tives of the Strategy and to enable comparisons of fed3 erally funded initiatives to identify those that are the 

4 most cost effective. 

5 ‘‘(3) GRANT APPLICATION STANDARDIZATION.— 

6 The Director, in consultation with the head of each 

7 National Drug Control Program Agency, shall develop 

8 a plan for coordinating and standardizing drug con9 trol grant application processes and develop a joint 

10 application to be used by all National Drug Control 

11 Program Agencies to reduce the administrative bur12 den and improve oversight of Federal funds. 

13 ‘‘(4) CENTRAL PORTAL.—The Director shall 

14 maintain on the public, electronic portal of the Office 

15 a list all drug control grant award opportunities 

16 available in a central location. The head of each Na17 tional Drug Control Program Agency shall provide a 

18 complete list of all drug control program grant award 

19 opportunities to the Director and annually update 

20 such list. 

21 ‘‘(5) REPORT TO CONGRESS.—The Director shall 

22 include in the assessment submitted to Congress under 

23 section 1006 an assessment on progress under this sec24 tion and the feasibility of block grants of Federal 

25 funding to States. 


pbinns on DSK79D2C42PROD with BILLS
53 

•HR 5925 RH

1 ‘‘§ 1008. Coordination and oversight of the national 

2 drug control program 

3 ‘‘(a) IN GENERAL.—The Director shall coordinate and 

4 oversee the implementation by the National Drug Control 

5 Program Agencies of the policies, goals, objectives, and pri6 orities established under section 1002(c)(1) and the fulfill7 ment of the responsibilities of such agencies under the Na8 tional Drug Control Strategy and make recommendations 

9 to National Drug Control Program Agency heads with re10 spect to implementation of National Drug Control Pro11 grams. 

12 ‘‘(b) DETAILING EMPLOYEES TO OTHER AGENCIES.— 

13 ‘‘(1) REQUEST.—The Director may request the 

14 head of an agency or program of the Federal Govern15 ment to place agency personnel who are engaged in 

16 drug control activities on temporary detail to another 

17 agency in order to implement the National Drug Con18 trol Strategy. 

19 ‘‘(2) AGENCY COMPLIANCE.—The head of the 

20 agency shall comply with such a request. 

21 ‘‘(3) MAXIMUM NUMBER OF DETAILEES.—The 

22 maximum number of personnel who may be detailed 

23 to another agency (including the Office) under this 

24 subsection during any fiscal year is— 

25 ‘‘(A) for the Department of Defense, 50; and 

26 ‘‘(B) for any other agency, 10. 


pbinns on DSK79D2C42PROD with BILLS
54 

•HR 5925 RH

1 ‘‘(c) DIRECTING FEDERAL FUNDING.—The Director 

2 may transfer funds made available to a National Drug 

3 Control Program Agency for National Drug Control Strat4 egy programs and activities to another account within such 

5 agency or to another National Drug Control Program Agen6 cy for National Drug Control Strategy programs and ac7 tivities, except that— 

8 ‘‘(1) the authority under this subsection may be 

9 limited in an annual appropriations Act or other 

10 provision of Federal law; 

11 ‘‘(2) the Director may exercise the authority 

12 under this subsection only with the concurrence of the 

13 head of each affected agency; 

14 ‘‘(3) in the case of an interagency transfer, the 

15 total amount of transfers under this subsection may 

16 not exceed 3 percent of the total amount of funds 

17 made available for National Drug Control Strategy 

18 programs and activities to the agency from which 

19 those funds are to be transferred; 

20 ‘‘(4) funds transferred to an agency under this 

21 subsection may only be used to increase the funding 

22 for programs or activities authorized by law; 

23 ‘‘(5) the Director shall— 

24 ‘‘(A) submit to the appropriate congres25 sional committees and any other applicable comVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00054 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
55 

•HR 5925 RH

1 mittees of jurisdiction, a reprogramming or 

2 transfer request in advance of any transfer under 

3 this subsection in accordance with the regula4 tions of the affected agency or agencies; and 

5 ‘‘(B) annually submit to the appropriate 

6 congressional committees a report describing the 

7 effect of all transfers of funds made pursuant to 

8 this subsection or section 1004(f) during the 12- 

9 month period preceding the date on which the re10 port is submitted; and 

11 ‘‘(6) funds may only be used for— 

12 ‘‘(A) expansion of demand reduction activi13 ties; 

14 ‘‘(B) interdiction of illicit drugs on the high 

15 seas, in United States territorial waters, and at 

16 United States ports of entry by officers and em17 ployees of Drug Control Program Agencies and 

18 domestic and foreign law enforcement officers; 

19 ‘‘(C) accurate assessment and monitoring of 

20 international drug production and interdiction 

21 programs and policies; 

22 ‘‘(D) activities to facilitate and enhance the 

23 sharing of domestic and foreign intelligence in24 formation among Drug Control Program Agen25 cies related to the production and trafficking of 


pbinns on DSK79D2C42PROD with BILLS
56 

•HR 5925 RH

1 drugs in the United States and foreign countries; 

2 and 

3 ‘‘(E) activities to prevent the diversion of 

4 prescription drugs for illicit use and research re5 lated to any of these activities. 

6 ‘‘(d) DIRECTING FEDERAL FUNDING TO RESPOND TO

7 EMERGING THREATS.— 

8 ‘‘(1) IN GENERAL.—The Director may transfer 

9 funds made available to a National Drug Control 

10 Program Agency for National Drug Control Strategy 

11 programs and activities to another account within 

12 such agency or to another National Drug Control 

13 Program Agency for National Drug Control Strategy 

14 programs and activities to implement the provisions 

15 of a plan developed under section 1009, except that— 

16 ‘‘(A) the authority under this subsection 

17 may be limited in an annual appropriations Act 

18 or other provision of Federal law; 

19 ‘‘(B) in the case of an interagency transfer, 

20 the total amount of transfers under this sub21 section may not exceed 10 percent of the total 

22 amount of funds made available for National 

23 Drug Control Strategy programs and activities 

24 to the agency from which those funds are to be 

25 transferred; 


pbinns on DSK79D2C42PROD with BILLS
57 

•HR 5925 RH

1 ‘‘(C) funds transferred to an agency under 

2 this subsection may only be used to increase the 

3 funding for programs or activities authorized by 

4 law; 

5 ‘‘(D) no transfer of funds under this sub6 section may result in a reduction in total Fed7 eral expenditures for substance use disorder 

8 treatment; 

9 ‘‘(E) the Director shall— 

10 ‘‘(i) submit to the appropriate congres11 sional committees and any other applicable 

12 committees of jurisdiction, a reprogram13 ming or transfer request in advance of any 

14 transfer under this subsection in accordance 

15 with the regulations of each affected agency; 

16 and 

17 ‘‘(ii) annually submit to the appro18 priate congressional committees a report de19 scribing the effect of all transfers of funds 

20 made pursuant to this subsection or section 

21 1004(f) during the 12-month period pre22 ceding the date on which the report is sub23 mitted; and 

24 ‘‘(F) funds may only be used for— 


pbinns on DSK79D2C42PROD with BILLS
58 

•HR 5925 RH

1 ‘‘(i) expansion of demand reduction ac2 tivities; 

3 ‘‘(ii) interdiction of illicit drugs on the 

4 high seas, in United States territorial 

5 waters, and at United States ports of entry 

6 by officers and employees of Drug Control 

7 Program agencies and domestic and foreign 

8 law enforcement officers; 

9 ‘‘(iii) accurate assessment and moni10 toring of international drug production and 

11 interdiction programs and policies; 

12 ‘‘(iv) activities to facilitate and en13 hance the sharing of domestic and foreign 

14 intelligence information among Drug Con15 trol Program Agencies related to the pro16 duction and trafficking of drugs in the 

17 United States and foreign countries; and 

18 ‘‘(v) activities to prevent the diversion 

19 of prescription drugs for illicit use and re20 search related to any of these activities. 

21 ‘‘(2) INADEQUACY OF TRANSFER.—In the event 

22 the authority under this subsection is inadequate to 

23 implement the provisions of a plan developed under 

24 section 1009, the Director shall submit a request for 


pbinns on DSK79D2C42PROD with BILLS
59 

•HR 5925 RH

1 funding to Congress as soon as the Director becomes 

2 aware of the need for additional funding. 

3 ‘‘(e) FUND CONTROL NOTICES.— 

4 ‘‘(1) IN GENERAL.—The Director may issue to 

5 the head of a National Drug Control Program Agency 

6 a fund control notice to ensure compliance with the 

7 National Drug Control Program Strategy. A fund 

8 control notice may direct that all or part of an 

9 amount appropriated to the National Drug Control 

10 Program Agency account be obligated by— 

11 ‘‘(A) months, fiscal year quarters, or other 

12 time periods; and 

13 ‘‘(B) activities, functions, projects, or object 

14 classes. 

15 ‘‘(2) UNAUTHORIZED OBLIGATION OR EXPENDI16 TURE PROHIBITED.—An officer or employee of a Na17 tional Drug Control Program Agency shall not make 

18 or authorize an expenditure or obligation contrary to 

19 a fund control notice issued by the Director. 

20 ‘‘(3) DISCIPLINARY ACTION FOR VIOLATION.—In 

21 the case of a violation of paragraph (2) by an officer 

22 or employee of a National Drug Control Program 

23 Agency, the head of the agency, upon the request of 

24 and in consultation with the Director, may subject 

25 the officer or employee to appropriate administrative 


pbinns on DSK79D2C42PROD with BILLS
60 

•HR 5925 RH

1 discipline, including, when circumstances warrant, 

2 suspension from duty without pay or removal from 

3 office. 

4 ‘‘(4) CONGRESSIONAL NOTICE.—Not later than 5 

5 days after issuance of a fund control notice, the Di6 rector shall submit a copy of such fund control notice 

7 to the appropriate congressional committees and make 

8 such notice publicly available. 

9 ‘‘(5) RESTRICTIONS.—The Director shall not 

10 issue a fund control notice to direct that all or part 

11 of an amount appropriated to the National Drug 

12 Control Program Agency account be obligated, modi13 fied, or altered in any manner contrary, in whole or 

14 in part, to a specific appropriation or statute. 

15 ‘‘(f) EXCLUSIONS.—The authorities described under 

16 subsections (c), (d), and (e) do not apply to any program 

17 under subchapter II or III. 

18 ‘‘(g) FOREIGN ASSISTANCE ACT PARTICIPATION.—The 

19 Director may participate in the drug certification process 

20 pursuant to section 490 of the Foreign Assistance Act of 

21 1961 (22 U.S.C. 2291j) and section 706 of the Department 

22 of State Authorization Act for Fiscal Year 2003 (22 U.S.C. 

23 229j–l). 

24 ‘‘(h) CERTIFICATIONS OF POLICY CHANGES TO DIREC25 TOR.— 


pbinns on DSK79D2C42PROD with BILLS
61 

•HR 5925 RH

1 ‘‘(1) IN GENERAL.—Subject to paragraph (2), the 

2 head of a National Drug Control Program Agency 

3 shall, unless exigent circumstances require otherwise, 

4 notify the Director in writing regarding any proposed 

5 change in policies relating to the activities of that 

6 agency under the National Drug Control Program 

7 prior to implementation of such change. The Director 

8 shall promptly review such proposed change and cer9 tify to the head of that agency in writing whether 

10 such change is consistent with the National Drug 

11 Control Strategy. 

12 ‘‘(2) EXCEPTION.—If prior notice of a proposed 

13 change under paragraph (1) is not practicable— 

14 ‘‘(A) the head of the National Drug Control 

15 Program Agency shall notify the Director of the 

16 proposed change as soon as practicable; and 

17 ‘‘(B) upon such notification, the Director 

18 shall review the change and certify to the head 

19 of that agency in writing whether the change is 

20 consistent with the National Drug Control Strat21 egy. 

22 ‘‘(i) WORK IN CONJUNCTION WITH ASSISTANT FOR

23 NATIONAL SECURITY AFFAIRS.—The Director shall, in any 

24 matter affecting national security interests, work in conVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00061 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
62 

•HR 5925 RH

1 junction with the Assistant to the President for National 

2 Security Affairs. 

3 ‘‘§ 1009. Emerging threats taskforce, plan, media cam4 paign 

5 ‘‘(a) EMERGING THREATS TASK FORCE.— 

6 ‘‘(1) EMERGING AND CONTINUING THREATS CO7 ORDINATOR.—The Director shall designate or appoint 

8 a United States Emerging and Continuing Threats 

9 Coordinator to perform the duties of that position de10 scribed in this section and such other duties as may 

11 be determined by the Director. The Director shall de12 termine whether the coordinator position is a career 

13 or noncareer position in the Senior Executive Service. 

14 ‘‘(2) ESTABLISHMENT AND MONITORING.—The 

15 Emerging and Continuing Threats Coordinator (re16 ferred to in this section as the ‘Coordinator’) shall 

17 monitor evolving and emerging drug threats in the 

18 United States and shall serve as Chair of an Emerg19 ing Threats Task Force (in this section, referred to as 

20 the ‘task force’). The Director shall appoint other 

21 members of the Task force, which shall include rep22 resentatives from— 

23 ‘‘(A) National Drug Control Program Agen24 cies or other agencies; 

25 ‘‘(B) State, local, and Tribal governments; 


pbinns on DSK79D2C42PROD with BILLS
63 

•HR 5925 RH

1 ‘‘(C) the Director of the Fusion Center es2 tablished in section 1013; and 

3 ‘‘(D) other entities as determined to be nec4 essary by the Director. 

5 ‘‘(3) INFORMATION REVIEW AND SHARING.— 

6 ‘‘(A) IN GENERAL.—The task force shall dis7 seminate and facilitate the sharing with Federal, 

8 State, local, and Tribal officials and other enti9 ties as determined by the Director of pertinent 

10 information and data relating to the following: 

11 ‘‘(i) Recent trends in drug supply and 

12 demand. 

13 ‘‘(ii) Fatal and nonfatal overdoses. 

14 ‘‘(iii) Demand for and availability of 

15 evidence-based substance use disorder treat16 ment, including the extent of the unmet 

17 treatment need, and treatment admission 

18 trends. 

19 ‘‘(iv) Recent trends in drug interdic20 tion, supply, and demand from State, local, 

21 and Tribal law enforcement agencies. 

22 ‘‘(v) Other subject matter as deter23 mined necessary by the Director. 

24 ‘‘(B) CONTRACT, AGREEMENT, AND OTHER

25 AUTHORITY.—The Director may award conVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00063 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
64 

•HR 5925 RH

1 tracts, enter into interagency agreements, man2 age individual projects, and conduct other oper3 ational activities in support of the identification 

4 of emerging threats and in support of the devel5 opment, implementation, and assessment of 

6 Emerging Threat Response Plans. 

7 ‘‘(C) DATA ANALYSIS ACTIVITIES.—In sup8 port of the task force, the National Drug Control 

9 Fusion Center is authorized to conduct and pro10 vide to the task force the results of data analysis 

11 activities that the task force requests to aid in 

12 their review of recent trends in the data dissemi13 nated under subparagraph (A). 

14 ‘‘(4) CRITERIA TO IDENTIFY EMERGING DRUG

15 THREATS.—Not later than 60 days after the date on 

16 which a task force first meets, the task force shall de17 velop and recommend to the Director criteria to be 

18 used to identify an emerging drug threat or the termi19 nation of an emerging drug threat designation based 

20 on information gathered by the task force in para21 graph (2), statistical data, and other evidence. 

22 ‘‘(5) MEETINGS.—The task force shall meet in 

23 person not less frequently than quarterly and at addi24 tional meetings if determined to be necessary by and 

25 at the call of the Chair to— 


pbinns on DSK79D2C42PROD with BILLS
65 

•HR 5925 RH

1 ‘‘(A) identify and discuss evolving and 

2 emerging drug trends in the United States using 

3 the criteria established in paragraph (3); 

4 ‘‘(B) formulate the plan described in sub5 section (c); 

6 ‘‘(C) oversee implementation of the plan de7 scribed in subsection (c); and 

8 ‘‘(D) provide such other advice to the Coor9 dinator and Director concerning strategy and 

10 policies for emerging drug threats and trends as 

11 the task force determines to be appropriate. 

12 ‘‘(b) DESIGNATION.— 

13 ‘‘(1) IN GENERAL.—The Director, in consultation 

14 with the Coordinator, the task force, and the head of 

15 each National Drug Control Program Agency, may 

16 designate an emerging drug threat in the United 

17 States. 

18 ‘‘(2) STANDARDS FOR DESIGNATION.—The Direc19 tor, in consultation with the Coordinator, shall pro20 mulgate and make publicly available standards by 

21 which a designation under paragraph (1) and the ter22 mination of such designation may be made. In devel23 oping such standards, the Director shall consider the 

24 recommendations of the task force and other criteria 

25 the Director considers to be appropriate. 


pbinns on DSK79D2C42PROD with BILLS
66 

•HR 5925 RH

1 ‘‘(3) PUBLIC STATEMENT REQUIRED.—The Di2 rector shall publish a public written statement on the 

3 portal of the Office explaining the designation of an 

4 emerging drug threat or the termination of such des5 ignation and shall notify the appropriate congres6 sional committees of the availability of such statement 

7 when a designation or termination of such designa8 tion has been made. 

9 ‘‘(c) PLAN.— 

10 ‘‘(1) PUBLIC AVAILABILITY OF PLAN.—Not later 

11 than 60 days after making a designation under sub12 section (b), the Director shall publish and make pub13 licly available an Emerging Threat Response Plan 

14 and notify the President and the appropriate congres15 sional committees of such plan’s availability. 

16 ‘‘(2) TIMING.—Not less frequently than every 90 

17 days after the date on which the plan is published 

18 under paragraph (1), the Director shall update the 

19 plan and report on implementation of the plan, until 

20 the Director issues the public statement required 

21 under subsection (b)(3) to terminate the emerging 

22 threat designation. 

23 ‘‘(3) CONTENTS OF AN EMERGING THREAT RE24 SPONSE PLAN.—The Director shall include in the 

25 plan— 


pbinns on DSK79D2C42PROD with BILLS
67 

•HR 5925 RH

1 ‘‘(A) a comprehensive strategic assessment 

2 of the emerging drug threat, including the cur3 rent availability of, demand for, and effectiveness 

4 of evidence-based prevention, treatment, and en5 forcement programs and efforts to respond to the 

6 emerging drug threat; 

7 ‘‘(B) comprehensive, research-based, long8 range, quantifiable goals for addressing the 

9 emerging drug threat, including for reducing the 

10 supply of the emerging drug threat and for ex11 panding the availability and effectiveness of evi12 dence-based substance use disorder treatment and 

13 prevention programs to reduce the demand for 

14 the emerging drug threat; 

15 ‘‘(C) performance measures pertaining to 

16 the plan’s goals, including quantifiable and 

17 measurable objectives and specific targets; 

18 ‘‘(D) the level of funding needed to imple19 ment the plan, including whether funding is 

20 available to be reprogrammed or transferred to 

21 support implementation of the plan or whether 

22 additional appropriations are necessary to im23 plement the plan; 

24 ‘‘(E) an implementation strategy for the 

25 education and public awareness campaign under 


pbinns on DSK79D2C42PROD with BILLS
68 

•HR 5925 RH

1 subsection (d), including goals as described 

2 under subparagraph (B) and performance meas3 ures, objectives, and targets, as described under 

4 subparagraph (C); and 

5 ‘‘(F) any other information necessary to in6 form the public of the status, progress, or re7 sponse of an emerging drug threat. 

8 ‘‘(4) IMPLEMENTATION.— 

9 ‘‘(A) IN GENERAL.—Not later than 90 days 

10 after the date on which a designation is made 

11 under subsection (b), the Director, in consulta12 tion with the President, the appropriate congres13 sional committees, and the head of each National 

14 Drug Control Program Agency, shall issue guid15 ance on implementation of the plan described in 

16 subsection (c) to the National Drug Control Pro17 gram Agencies and any other relevant agency de18 termined to be necessary by the Director. 

19 ‘‘(B) COORDINATOR’S RESPONSIBILITIES.— 

20 The Coordinator shall— 

21 ‘‘(i) direct the implementation of the 

22 plan among the agencies identified in the 

23 plan, State, local, and Tribal governments, 

24 and other relevant entities; 


pbinns on DSK79D2C42PROD with BILLS
69 

•HR 5925 RH

1 ‘‘(ii) facilitate information-sharing be2 tween agencies identified in the plan, State, 

3 local, and Tribal governments, and other 

4 relevant entities; and 

5 ‘‘(iii) monitor implementation of the 

6 plan by coordinating the development and 

7 implementation of collection and reporting 

8 systems to support performance measure9 ment and adherence to the plan by agencies 

10 identified in plan, where appropriate. 

11 ‘‘(C) REPORTING.—Not later than 180 days 

12 after designation under subsection (b) and in ac13 cordance with paragraph (2)(C), the head of each 

14 agency identified in the plan shall submit to the 

15 Coordinator a report on implementation of the 

16 plan. 

17 ‘‘(d) EDUCATION AND PUBLIC AWARENESS CAMPAIGN

18 FOR EMERGING DRUG THREATS.— 

19 ‘‘(1) IN GENERAL.—Not later than 90 days after 

20 a designation under subsection (b), the Director shall 

21 establish and implement an evidence-based substance 

22 use prevention education and public awareness cam23 paign to inform the public about the dangers of any 

24 drug designated as an emerging drug threat. Such 

25 campaign shall— 


pbinns on DSK79D2C42PROD with BILLS
70 

•HR 5925 RH

1 ‘‘(A) educate the public about the dangers of 

2 such drug, including patient and family edu3 cation about the characteristics and hazards of 

4 such drugs and methods to safeguard against 

5 such dangers, including the safe disposal of such 

6 drugs; 

7 ‘‘(B) support evidence-based prevention pro8 grams targeting audiences’ attitudes, percep9 tions, and beliefs concerning substance use and 

10 intentions to initiate or continue such use; 

11 ‘‘(C) increase awareness of the negative con12 sequences of drug use; 

13 ‘‘(D) encourage individuals affected by sub14 stance use disorders to seek treatment and pro15 vide such individuals with information on how 

16 to recognize addiction issues, what forms of evi17 dence-based treatment options are available, and 

18 how to access such treatment; and 

19 ‘‘(E) combat the stigma of addiction and 

20 substance use disorders, including the stigma of 

21 treating such disorders with medication-assisted 

22 treatment therapies. 

23 ‘‘(2) CONSULTATION.—For the planning of the 

24 campaign under paragraph (1), the Secretary shall 

25 consult with— 


pbinns on DSK79D2C42PROD with BILLS
71 

•HR 5925 RH

1 ‘‘(A) the head of any appropriate National 

2 Drug Control Program Agency to obtain advice 

3 on evidence-based scientific information for pol4 icy, program development, and evaluation; 

5 ‘‘(B) experts in evidence-based media cam6 paigns, education, evaluation, and communica7 tion; 

8 ‘‘(C) experts on the designated drug; 

9 ‘‘(D) State, local, and Tribal government of10 ficials and relevant agencies; 

11 ‘‘(E) the public; 

12 ‘‘(F) appropriate congressional committees; 

13 and 

14 ‘‘(G) any other affected person. 

15 ‘‘(3) GIFTS AND DONATIONS.— 

16 ‘‘(A) IN GENERAL.—The Director may ac17 cept gifts and donations (in cash or in kind, in18 cluding voluntary and uncompensated services or 

19 property), which shall be available until ex20 pended, for the purpose of supporting the edu21 cation and outreach campaign authorized in this 

22 section, including the media campaign. 

23 ‘‘(B) ETHICS GUIDELINES.—The Director 

24 shall establish written guidelines setting forth the 

25 criteria to be used in determining whether a gift 


pbinns on DSK79D2C42PROD with BILLS
72 

•HR 5925 RH

1 or donation should be declined under this section 

2 because the acceptance of the gift or donation 

3 would— 

4 ‘‘(i) reflect unfavorably upon the abil5 ity of the Director or the Office, or any em6 ployee of the Office, to carry out responsibil7 ities or official duties under this chapter in 

8 a fair and objective manner; or 

9 ‘‘(ii) compromise the integrity or the 

10 appearance of integrity of programs or serv11 ices provided under this chapter or of any 

12 official involved in those programs or serv13 ices. 

14 ‘‘(C) ANNUAL REPORT REQUIRED.—Not 

15 later than the first Monday in the February of 

16 each year, the Director shall submit to the ap17 propriate congressional committees an annual 

18 report that identifies the sources of any gift or 

19 donation accepted by the Office or any con20 tractor acting on behalf of the Office, under this 

21 subsection, including the value of each gift and 

22 donation provided by each source of the gift. 

23 ‘‘(4) IMPLEMENTATION.— 


pbinns on DSK79D2C42PROD with BILLS
73 

•HR 5925 RH

1 ‘‘(A) IN GENERAL.—For any campaign es2 tablished under this subsection, the Director shall 

3 ensure the following: 

4 ‘‘(i) Implementation is evidence-based, 

5 meets accepted standards for public aware6 ness campaigns, and uses available re7 sources in a manner to make the most 

8 progress toward achieving the goals identi9 fied in the emerging threats plan and para10 graph (1). 

11 ‘‘(ii) Information disseminated through 

12 the campaign is accurate. 

13 ‘‘(iii) The Director approves the strat14 egy of the campaign, all material distrib15 uted through the campaign, and the use of 

16 any Federal funds used for the campaign. 

17 ‘‘(iv) The campaign is designed using 

18 strategies found to be most effective at 

19 achieving such goals, which may include— 

20 ‘‘(I) a media campaign, as de21 scribed in subparagraph (B); 

22 ‘‘(II) local, regional, or popu23 lation specific messaging; 

24 ‘‘(III) establishing partnerships 

25 and promoting coordination among 


pbinns on DSK79D2C42PROD with BILLS
74 

•HR 5925 RH

1 community stakeholders, including 

2 public, nonprofit organizations, and 

3 for profit entities; 

4 ‘‘(IV) providing support, training, 

5 and technical assistance to establish 

6 and expand school and community 

7 prevention programs; 

8 ‘‘(V) creating websites to publicize 

9 and disseminate information; 

10 ‘‘(VI) conducting outreach and 

11 providing educational resources for 

12 parents; 

13 ‘‘(VII) establishing State or re14 gional advisory councils to provide 

15 input and recommendations to raise 

16 awareness regarding the drug des17 ignated as an emerging drug threat; 

18 ‘‘(VIII) collaborating with law en19 forcement; and 

20 ‘‘(IX) support for school-based 

21 public health education classes to im22 prove teen knowledge about the effects 

23 of such designated drug. 


pbinns on DSK79D2C42PROD with BILLS
75 

•HR 5925 RH

1 ‘‘(B) MEDIA CAMPAIGN.—Any campaign 

2 implemented under this subsection may include 

3 a media component, which— 

4 ‘‘(i) shall be designed to prevent the use 

5 of the drug designated as an emerging drug 

6 threat and to achieve the goals of paragraph 

7 (1); 

8 ‘‘(ii) shall be carried out through com9 petitively awarded contracts to entities pro10 viding for the professional production and 

11 design of such campaign; and 

12 ‘‘(iii) may include the use of television, 

13 radio, Internet, social media, and other 

14 commercial marketing venues and may be 

15 targeted to specific age groups based on 

16 peer-reviewed social research. 

17 ‘‘(C) REQUIRED NOTICE FOR COMMUNICA18 TION FROM THE OFFICE.—Any communication, 

19 including an advertisement, paid for or other20 wise disseminated by the Office directly or 

21 through a contract awarded by the Office shall 

22 include a prominent notice informing the audi23 ence that the communication was a paid for by 

24 of the Office. 

25 ‘‘(5) EVALUATION.— 


pbinns on DSK79D2C42PROD with BILLS
76 

•HR 5925 RH

1 ‘‘(A) PERFORMANCE EVALUATION.—The Di2 rector shall include an evaluation of the cam3 paign in the annual assessment under section 

4 1006, which shall include the following: 

5 ‘‘(i) A performance evaluation of the 

6 campaign, including progress toward meet7 ing the goals, objectives, measures, and tar8 gets identified in the emerging threats plan. 

9 ‘‘(ii) A description of all policies and 

10 practices to eliminate the potential for 

11 waste, fraud, abuse, and to ensure Federal 

12 funds are used responsibly. 

13 ‘‘(iii) A list of all contracts or other 

14 agreements entered into to implement the 

15 campaign. 

16 ‘‘(iv) The results of any financial audit 

17 of the campaign. 

18 ‘‘(v) A description of any evidence used 

19 to develop the campaign. 

20 ‘‘(B) INDEPENDENT EVALUATION.—Not 

21 later than 180 days after establishing a cam22 paign under paragraph (1) and not less than 

23 frequently than every two years thereafter, the 

24 Director shall— 


pbinns on DSK79D2C42PROD with BILLS
77 

•HR 5925 RH

1 ‘‘(i) designate an independent entity to 

2 evaluate the effectiveness of the campaign 

3 with meeting the goals established in the 

4 emerging threat plan and paragraph (1); 

5 and 

6 ‘‘(ii) submit the results of the inde7 pendent evaluation to the appropriate con8 gressional committees. 

9 ‘‘(6) FUNDING PROHIBITIONS.—None of the 

10 amounts made available under this subsection may be 

11 obligated for any of the following: 

12 ‘‘(A) To supplant current anti-drug commu13 nity-based coalitions. 

14 ‘‘(B) To supplant pro bono public service 

15 time donated by national and local broadcasting 

16 network for other public services campaigns. 

17 ‘‘(C) For partisan political purposes, or ex18 press advocacy in support of or to defeat any 

19 clearly identified candidate, clearly identified 

20 ballot initiative, or clearly identified legislative 

21 or regulatory proposal. 

22 ‘‘(D) For any advocacy in support of any 

23 particular company, industry association, or ad24 vocacy group or the explicit policy positions held 

25 by such groups. 


pbinns on DSK79D2C42PROD with BILLS
78 

•HR 5925 RH

1 ‘‘(E) To direct any individuals to a specific 

2 type of substance use disorder treatment, treat3 ment facility, medical provider, or form of medi4 cation assisted treatment. 

5 ‘‘(F) To fund any advertising that features 

6 any elected officials, persons seeking elected of7 fice, cabinet level officials, or other Federal offi8 cials employed pursuant to section 213 of Sched9 ule C of title 5, Code of Federal Regulations. 

10 ‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There is 

11 authorized to be appropriated to the Office to carry out this 

12 section, $25,000,000 for each of fiscal years 2019 through 

13 2023. 

14 ‘‘§ 1010. National and international coordination 

15 ‘‘(a) DISSEMINATION OF RESEARCH AND INFORMATION

16 TO STATES.—The Director shall ensure that drug control 

17 research and information is effectively disseminated by Na18 tional Drug Control Program Agencies to State and local 

19 governments and nongovernmental entities involved in de20 mand reduction by— 

21 ‘‘(1) encouraging formal consultation between 

22 any such agency that conducts or sponsors research, 

23 and any such agency that disseminates information 

24 in developing research and information product devel25 opment agendas; 


pbinns on DSK79D2C42PROD with BILLS
79 

•HR 5925 RH

1 ‘‘(2) encouraging such agencies (as appropriate) 

2 to develop and implement dissemination plans that 

3 specifically target State and local governments and 

4 nongovernmental entities involved in demand reduc5 tion; and 

6 ‘‘(3) supporting the substance abuse information 

7 clearinghouse administered by the Administrator of 

8 the Substance Abuse and Mental Health Services Ad9 ministration and established in section 501(d)(16) of 

10 the Public Health Service Act by— 

11 ‘‘(A) encouraging all National Drug Control 

12 Program Agencies to provide all appropriate and 

13 relevant information; and 

14 ‘‘(B) supporting the dissemination of infor15 mation to all interested entities. 

16 ‘‘(b) STANDARDS.— 

17 ‘‘(1) DEVELOPMENT.—The Director shall coordi18 nate the development of evidence-based standards de19 veloped by National Drug Control Program Agencies 

20 and other relevant agencies and non-Federal entities 

21 to State, local, and Tribal governments and non22 governmental entities related to drug control policies, 

23 practices, and procedures, such as the investigation of 

24 drug-related deaths, by— 


pbinns on DSK79D2C42PROD with BILLS
80 

•HR 5925 RH

1 ‘‘(A) encouraging appropriate agencies and 

2 State, local, and Tribal governments to develop 

3 data standards for drug control practices and 

4 procedures and related statistical data; 

5 ‘‘(B) encouraging information sharing be6 tween appropriate agencies and State, local, and 

7 Tribal governments of relevant drug control in8 formation and data; 

9 ‘‘(C) establishing a working group of agen10 cies, State, local, and Tribal governments, and 

11 other relevant stakeholders to discuss and develop 

12 such standards; and 

13 ‘‘(D) facilitating collaboration among agen14 cies, non-Federal entities, States, local, and Trib15 al governments, and nongovernmental agencies. 

16 ‘‘(2) IMPLEMENTATION.—The Director shall pro17 mote the implementation of the standards described in 

18 paragraph (1) by— 

19 ‘‘(A) encouraging adoption by providing the 

20 standards to State and local governments 

21 through the internet, annual publications or 

22 periodicals, and other widely-disseminated 

23 means; and 


pbinns on DSK79D2C42PROD with BILLS
81 

•HR 5925 RH

1 ‘‘(B) facilitating the use and dissemination 

2 of such standards among State and local govern3 ments by— 

4 ‘‘(i) providing technical assistance to 

5 State, local, and Tribal governments seeking 

6 to adopt or implement such standards; and 

7 ‘‘(ii) coordinating seminars and train8 ing sessions for State, local, and Tribal gov9 ernments seeking to adopt or implement 

10 such standards. 

11 ‘‘(c) PRIVATE SECTOR.— 

12 ‘‘(1) IN GENERAL.—The Director or the head of 

13 a National Drug Control Program (as designated by 

14 the Director) shall coordinate with the private sector 

15 to promote private research and development of medi16 cations to treat or prevent addiction, including re17 search and development for non-addictive pain man18 agement medication, abuse deterrent formulations, 

19 medication-assisted treatment, and other addiction re20 search determined to be necessary by the Director 

21 by— 

22 ‘‘(A) encouraging the sharing of informa23 tion regarding evidence-based treatment addic24 tion findings and related data between agencies 

25 and the private sector, as appropriate; 


pbinns on DSK79D2C42PROD with BILLS
82 

•HR 5925 RH

1 ‘‘(B) encouraging collaboration between ap2 propriate agencies and the private sector; and 

3 ‘‘(C) providing private sector entities with 

4 relevant statistical data and information to en5 hance research as permissible. 

6 ‘‘(2) WORKING GROUP.—The Director may estab7 lish a working group of National Drug Control Pro8 gram Agencies, State, local, and Tribal governments, 

9 and the private sector stakeholders to discuss and dis10 seminate best practices, research and development, 

11 and other related issues, as appropriate. 

12 ‘‘(d) MODEL ACTS PROGRAM.— 

13 ‘‘(1) IN GENERAL.—The Director shall provide 

14 for or shall enter into an agreement with a nonprofit 

15 organization to— 

16 ‘‘(A) advise States on establishing laws and 

17 policies to address illicit drug use issues; and 

18 ‘‘(B) revise such model State drug laws and 

19 draft supplementary model State laws to take 

20 into consideration changes in illicit drug use 

21 issues in the State involved. 

22 ‘‘(2) AUTHORIZATION OF APPROPRIATIONS.— 

23 There is authorized to be appropriated to carry out 

24 this subsection $1,250,000 for each of fiscal years 

25 2019 through 2023. 


pbinns on DSK79D2C42PROD with BILLS
83 

•HR 5925 RH

1 ‘‘(e) DRUG COURT TRAINING AND TECHNICAL ASSIST2 ANCE PROGRAM.— 

3 ‘‘(1) GRANTS AUTHORIZED.—The Director may 

4 make a grant to a nonprofit organization for the pur5 pose of providing training and technical assistance to 

6 drug courts. 

7 ‘‘(2) AUTHORIZATION OF APPROPRIATIONS.— 

8 There is authorized to be appropriated to carry out 

9 this subsection $2,000,000 for each of fiscal years 

10 2019 through 2023. 

11 ‘‘(f) INTERNATIONAL COORDINATION.—The Director 

12 shall facilitate international drug control coordination ef13 forts. 

14 ‘‘(g) STATE, LOCAL, AND TRIBAL AFFAIRS COORDI15 NATOR.—The Director shall designate or appoint a United 

16 States State, Local, and Tribal Affairs Coordinator to per17 form the duties of the Office outlined in this section and 

18 section 1005 and such other duties as may be determined 

19 by the Director with respect to coordination of drug control 

20 efforts between agencies and State, local, and Tribal govern21 ments. The Director shall determine whether the coordinator 

22 position is a career or noncareer position in the Senior Ex23 ecutive Service. 

24 ‘‘§ 1011. Interdiction 

25 ‘‘(a) UNITED STATES INTERDICTION COORDINATOR.— 


pbinns on DSK79D2C42PROD with BILLS
84 

•HR 5925 RH

1 ‘‘(1) IN GENERAL.—The Director shall designate 

2 or appoint a United States Interdiction Coordinator 

3 to perform the duties of that position described in 

4 paragraph (2) and such other duties as may be deter5 mined by the Director with respect to coordination of 

6 efforts to interdict illicit drugs from entering the 

7 United States. 

8 ‘‘(2) RESPONSIBILITIES.—The United States 

9 Interdiction Coordinator shall be responsible to the 

10 Director for— 

11 ‘‘(A) coordinating the interdiction activities 

12 of the National Drug Control Program Agencies 

13 to ensure consistency with the National Drug 

14 Control Strategy; 

15 ‘‘(B) on behalf of the Director, developing 

16 and issuing, on or before March 1 of each year 

17 and in accordance with paragraph (4), a Na18 tional Interdiction Command and Control Plan 

19 to ensure the coordination and consistency de20 scribed in subparagraph (A); 

21 ‘‘(C) assessing the sufficiency of assets com22 mitted to illicit drug interdiction by the relevant 

23 National Drug Control Program Agencies; and 

24 ‘‘(D) advising the Director on the efforts of 

25 each National Drug Control Program Agency to 


pbinns on DSK79D2C42PROD with BILLS
85 

•HR 5925 RH

1 implement the National Interdiction Command 

2 and Control Plan. 

3 ‘‘(3) STAFF.—The Director shall assign such per4 manent staff of the Office as he considers appropriate 

5 to assist the United States Interdiction Coordinator 

6 to carry out the responsibilities described in para7 graph (2), and may request that appropriate Na8 tional Drug Control Program Agencies detail or as9 sign staff to assist in carrying out such activities. 

10 ‘‘(4) NATIONAL INTERDICTION COMMAND AND

11 CONTROL PLAN.— 

12 ‘‘(A) PURPOSES.—The National Interdic13 tion Command and Control Plan— 

14 ‘‘(i) shall set forth the Government’s 

15 strategy for drug interdiction; 

16 ‘‘(ii) shall state the specific roles and 

17 responsibilities of the relevant National 

18 Drug Control Program Agencies for imple19 menting that strategy; 

20 ‘‘(iii) shall identify the specific re21 sources required to enable the relevant Na22 tional Drug Control Program Agencies to 

23 implement that strategy; and 


pbinns on DSK79D2C42PROD with BILLS
86 

•HR 5925 RH

1 ‘‘(iv) may include recommendations 

2 about changes to existing agency authorities 

3 or laws governing interagency relationships. 

4 ‘‘(B) CONSULTATION WITH OTHER AGEN5 CIES.—Before the submission of the National 

6 Drug Control Strategy or annual supplement re7 quired under section 1005(d), as applicable, the 

8 United States Interdiction Coordinator shall 

9 issue the National Interdiction Command and 

10 Control Plan, in consultation with the other 

11 members of the Interdiction Committee described 

12 in subsection (c). 

13 ‘‘(C) REPORT TO CONGRESS.—On or before 

14 March 1 of each year, the Director, through the 

15 United States Interdiction Coordinator, shall 

16 provide to the appropriate congressional commit17 tees, to the Committee on Armed Services and the 

18 Committee on Homeland Security of the House 

19 of Representatives, and to the Committee on 

20 Homeland Security and Governmental Affairs 

21 and the Committee on Armed Services of the 

22 Senate, a report that includes— 

23 ‘‘(i) a copy of that year’s National 

24 Interdiction Command and Control Plan; 


pbinns on DSK79D2C42PROD with BILLS
87 

•HR 5925 RH

1 ‘‘(ii) information for the previous 10 

2 years regarding the number and type of sei3 zures of drugs by each National Drug Con4 trol Program Agency conducting drug inter5 diction activities and statistical informa6 tion on the geographic areas of such sei7 zures; and 

8 ‘‘(iii) information for the previous 10 

9 years regarding the number of air and mar10 itime patrol hours undertaken by each Na11 tional Drug Control Program Agency con12 ducting drug interdiction activities and sta13 tistical information on the geographic areas 

14 in which such patrol hours took place. 

15 ‘‘(D) CLASSIFIED ANNEX.—The report sub16 mitted pursuant to subparagraph (C) may in17 clude a classified annex. 

18 ‘‘(b) INTERDICTION COMMITTEE.— 

19 ‘‘(1) IN GENERAL.—The Interdiction Committee 

20 shall meet to— 

21 ‘‘(A) discuss and resolve issues related to the 

22 coordination, oversight, and integration of inter23 national, border, and domestic drug interdiction 

24 efforts in support of the National Drug Control 

25 Strategy; 


pbinns on DSK79D2C42PROD with BILLS
88 

•HR 5925 RH

1 ‘‘(B) review the annual National Interdic2 tion Command and Control Plan, and provide 

3 advice to the Director and the United States 

4 Interdiction Coordinator concerning that plan; 

5 and 

6 ‘‘(C) provide such other advice to the Direc7 tor concerning drug interdiction strategy and 

8 policies as the committee determines is appro9 priate. 

10 ‘‘(2) CHAIR.—The Director shall designate one of 

11 the members of the Interdiction Committee to serve as 

12 chair. 

13 ‘‘(3) MEETINGS.—The members of the Interdic14 tion Committee shall meet, in person and not through 

15 any delegate or representative, at least once per cal16 endar year, before March 1. At the call of the Director 

17 or the chair, the Interdiction Committee may hold ad18 ditional meetings, which shall be attended by the 

19 members in person, or through such delegates or rep20 resentatives as the members may choose. 

21 ‘‘(4) REPORT.—Not later than September 30 of 

22 each year, the chair of the Interdiction Committee 

23 shall submit to the Director and to the appropriate 

24 congressional committees a report describing the re25 sults of the meetings and any significant findings of 


pbinns on DSK79D2C42PROD with BILLS
89 

•HR 5925 RH

1 the committee during the previous 12 months. Such 

2 report may include a classified annex. 

3 ‘‘§ 1012. Treatment coordinator 

4 ‘‘(a) UNITED STATES TREATMENT COORDINATOR.— 

5 ‘‘(1) IN GENERAL.—The Director shall designate 

6 or appoint a United States Treatment Coordinator to 

7 perform the responsibilities of that position described 

8 in paragraph (2) and such other duties as may be de9 termined by the Director with respect to coordination 

10 of efforts to expand the availability of substance use 

11 disorder treatment with the goal of eliminating the 

12 unmet treatment need. 

13 ‘‘(2) RESPONSIBILITIES.—The United States 

14 Treatment Coordinator shall be responsible to the Di15 rector for— 

16 ‘‘(A) coordinating the activities of the Na17 tional Drug Control Program Agencies under18 taken to expand the availability of evidence19 based substance use disorder treatment to ensure 

20 consistency with the National Drug Control 

21 Strategy; 

22 ‘‘(B) on behalf of the Director, developing 

23 and issuing, on or before March 1 of each year 

24 and in accordance with paragraph (4), a Na25 tional Treatment Plan to ensure the coordinaVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00089 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
90 

•HR 5925 RH

1 tion and consistency described in subparagraph 

2 (A); 

3 ‘‘(C) assessing the sufficiency of Federal re4 sources directed to substance use disorder treat5 ment by the relevant National Drug Control Pro6 gram Agencies; 

7 ‘‘(D) encouraging the adoption by all sub8 stance use disorder treatment providers of evi9 dence-based standards to guide all aspects of 

10 treatment provided; and 

11 ‘‘(E) advising the Director on the efforts of 

12 each National Drug Control Program Agency to 

13 implement the National Treatment Plan. 

14 ‘‘(3) STAFF.—The Director shall assign such per15 manent staff of the Office of the United States Treat16 ment Coordinator as the Director determines to be ap17 propriate to assist the United States Treatment Coor18 dinator to carry out the responsibilities described in 

19 paragraph (2), and may request that appropriate Na20 tional Drug Control Program Agencies detail or as21 sign staff to assist in carrying out such responsibil22 ities. 

23 ‘‘(4) NATIONAL TREATMENT PLAN.— 

24 ‘‘(A) PURPOSES.—The National Treatment 

25 Plan— 


pbinns on DSK79D2C42PROD with BILLS
91 

•HR 5925 RH

1 ‘‘(i) shall identify the unmet need for 

2 treatment for evidence-based substance use 

3 disorders including opioid use disorders, 

4 and set forth the Government’s strategy for 

5 closing the gap between available and need6 ed treatment through all sources; 

7 ‘‘(ii) shall describe the specific roles 

8 and responsibilities of the relevant National 

9 Drug Control Program Agencies for imple10 menting that strategy; 

11 ‘‘(iii) shall identify the specific re12 sources required to enable the relevant Na13 tional Drug Control Program Agencies to 

14 implement that strategy; 

15 ‘‘(iv) shall identify the resources, in16 cluding private sources, required to elimi17 nate the unmet need for evidence-based sub18 stance use disorder treatment; and 

19 ‘‘(v) may include recommendations 

20 about changes to existing agency authorities 

21 or laws governing interagency relationships. 

22 ‘‘(B) CONSULTATION WITH OTHER AGEN23 CIES.—Before the submission of the National 

24 Treatment Strategy or annual supplement re25 quired under section 1005(d), as applicable, the 


pbinns on DSK79D2C42PROD with BILLS
92 

•HR 5925 RH

1 United States Treatment Coordinator shall issue 

2 the National Treatment Plan, in consultation 

3 with the other members of the Interdiction Com4 mittee described in subsection (b). 

5 ‘‘(C) REPORT TO CONGRESS.—On or before 

6 March 1 of each year, the Director, through the 

7 United States Treatment Coordinator, shall pro8 vide to the appropriate congressional committees 

9 a report that includes a copy of that year’s Na10 tional Treatment Plan; 

11 ‘‘(b) TREATMENT COMMITTEE.— 

12 ‘‘(1) IN GENERAL.—The Treatment Committee 

13 shall meet to— 

14 ‘‘(A) review and discuss the adequacy of 

15 evidence-based substance use disorder treatment 

16 as well as the unmet need for treatment; 

17 ‘‘(B) review and discuss the status of the 

18 implementation of the National Treatment Plan; 

19 and 

20 ‘‘(C) provide such other advice to the Direc21 tor concerning substance use disorder treatment 

22 initiatives as the committee determines is appro23 priate. 


pbinns on DSK79D2C42PROD with BILLS
93 

•HR 5925 RH

1 ‘‘(2) CHAIR.—The Director shall designate one of 

2 the members of the Treatment Committee to serve as 

3 chair. 

4 ‘‘(3) MEETINGS.—The members of the Treatment 

5 Committee shall meet, in person and not through any 

6 delegate or representative, at least once per calendar 

7 year, before March 1. At the call of the Director or 

8 the chair, the Treatment Committee may hold addi9 tional meetings, which shall be attended by the mem10 bers in person, or through such delegates or represent11 atives as the members may choose. 

12 ‘‘(4) REPORT.—Not later than September 30 of 

13 each year, the chair of the Treatment Committee shall 

14 submit to the Director and to the appropriate con15 gressional committees a report describing the results 

16 of the meetings and any significant findings of the 

17 committee during the previous 12 months. Such re18 port may include a classified annex. 

19 ‘‘§ 1013. Critical information coordination 

20 ‘‘(a) NATIONAL DRUG CONTROL FUSION CENTER.— 

21 ‘‘(1) ESTABLISHMENT.—The Director shall, in 

22 consultation with the head of each National Drug 

23 Control Program Agency, designate an agency to es24 tablish a National Drug Control Fusion Center (re25 ferred to in this section as the ‘Center’). The Center 


pbinns on DSK79D2C42PROD with BILLS
94 

•HR 5925 RH

1 shall operate under the authority of the Director and 

2 shall work with the National Drug Control Program 

3 Agencies to collect, compile, analyze, and facilitate the 

4 sharing of data on the use of illicit drugs, treatment 

5 for substance use disorder, and interdiction of illicit 

6 drugs. The Center shall be considered a ‘statistical 

7 agency or unit’, as that term is defined in section 502 

8 of the Confidential Information Protection and Sta9 tistical Efficiency Act of 2002 (44 U.S.C. 3501 note) 

10 and shall have the necessary independence to ensure 

11 any data or information acquired by an agency 

12 under a pledge of confidentiality and for exclusively 

13 statistical purposes is used exclusively for statistical 

14 purposes. 

15 ‘‘(2) CENTER DIRECTOR.—There shall be at the 

16 head of the Center a Center Director who shall be ap17 pointed by the Director from among individuals 

18 qualified and distinguished in data governance and 

19 statistical analysis. 

20 ‘‘(3) DATA COMPILATION.—The Director, acting 

21 through the Center Director, shall do the following: 

22 ‘‘(A) Coordinate data collection activities 

23 among the National Drug Control Program 

24 Agencies. 


pbinns on DSK79D2C42PROD with BILLS
95 

•HR 5925 RH

1 ‘‘(B) Collect information not otherwise col2 lected by National Drug Control Program Agen3 cies as necessary to inform the National Drug 

4 Control Strategy. 

5 ‘‘(C) Compile and analyze any data re6 quired to be collected under this chapter. 

7 ‘‘(D) Disseminate technology, as appro8 priate, to States and local jurisdictions to enable 

9 or improve the collection of data on drug use, in10 cluding the recordation of the occurrence of fatal 

11 and non-fatal drug overdoses. 

12 ‘‘(E) Compile information collected by Na13 tional Drug Control Program Agencies on grants 

14 issued through any National Drug Control Pro15 gram, including for any grant the following: 

16 ‘‘(i) The recipient. 

17 ‘‘(ii) The amount. 

18 ‘‘(iii) The intended purpose. 

19 ‘‘(iv) Any evidence of the efficacy of the 

20 outcomes achieved by the program funded 

21 through the grant. 

22 ‘‘(v) Any assessments of how the grant 

23 met its intended purpose. 

24 ‘‘(4) TOXICOLOGY SCREENING.— 


pbinns on DSK79D2C42PROD with BILLS
96 

•HR 5925 RH

1 ‘‘(A) ESTABLISHMENT.—The Center Direc2 tor may establish a toxicology screening program 

3 that engages in— 

4 ‘‘(i) secondary analysis of urine sam5 ples that would otherwise be discarded by— 

6 ‘‘(I) hospitals and drug treatment 

7 programs; 

8 ‘‘(II) correctional facilities, book9 ing sites, probation programs, drug 

10 courts, and related facilities; and 

11 ‘‘(III) coroners and medical exam12 iners; and 

13 ‘‘(ii) analysis of other physical sam14 ples, as determined by the Center Director 

15 to be valuable for understanding the preva16 lence of any illicit drug. 

17 ‘‘(B) DE-IDENTIFICATION OF INFORMA18 TION.—The Center Director shall ensure that no 

19 samples have any personally identifiable infor20 mation prior to collection. 

21 ‘‘(C) LIMITATION ON USE.—No data ob22 tained from analysis conducted under this para23 graph may be used as evidence in any pro24 ceeding. 


pbinns on DSK79D2C42PROD with BILLS
97 

•HR 5925 RH

1 ‘‘(D) STATE PROGRAM.—The Center Direc2 tor may establish a program that enables States 

3 and local jurisdictions to submit up to 20 urine 

4 samples per year for toxicology analysis for the 

5 purposes of identifying substances present in in6 dividuals who have suffered fatal drug overdoses. 

7 ‘‘(5) AUTHORITY TO CONTRACT.—The Director 

8 may award contracts, enter into interagency agree9 ments, manage individual projects, and conduct other 

10 operational activities under this subsection. 

11 ‘‘(b) CRITICAL DRUG CONTROL INFORMATION AND

12 EVIDENCE PLAN.— 

13 ‘‘(1) IN GENERAL.—Not later than the first Mon14 day in February of each year, the Director shall sub15 mit to Congress a systematic plan for increasing data 

16 collection to enable real-time surveillance of drug con17 trol threats, developing analysis and monitoring ca18 pabilities, and identifying and addressing policy 

19 questions relevant to the National Drug Control Pol20 icy, Strategy, and Program. Such plan shall be made 

21 available on the public online portal of the Office, 

22 shall cover at least a 4-year period beginning with the 

23 first fiscal year following the fiscal year in which the 

24 plan is submitted and published, and contain the fol25 lowing: 


pbinns on DSK79D2C42PROD with BILLS
98 

•HR 5925 RH

1 ‘‘(A) A list of policy-relevant questions for 

2 which the Director and each National Drug Con3 trol Program Agency intends to develop evidence 

4 to support the National Drug Control Program 

5 and Strategy. 

6 ‘‘(B) A list of data the Director and each 

7 National Drug Control Program Agency intends 

8 to collect, use, or acquire to facilitate the use of 

9 evidence in drug control policymaking and mon10 itoring. 

11 ‘‘(C) A list of methods and analytical ap12 proaches that may be used to develop evidence to 

13 support the National Drug Control Program and 

14 Strategy and related policy. 

15 ‘‘(D) A list of any challenges to developing 

16 evidence to support policymaking, including any 

17 barriers to accessing, collecting, or using relevant 

18 data. 

19 ‘‘(E) A description of the steps the Director 

20 and the head of each National Drug Control Pro21 gram Agency will take to effectuate the plan. 

22 ‘‘(F) Any other relevant information as de23 termined by the Director. 


pbinns on DSK79D2C42PROD with BILLS
99 

•HR 5925 RH

1 ‘‘(2) CONSULTATION.—In developing the plan re2 quired under paragraph (1), the Director shall con3 sult with the following: 

4 ‘‘(A) The public. 

5 ‘‘(B) Any evaluation or analysis units and 

6 personnel of the Office. 

7 ‘‘(C) Office officials responsible for imple8 menting privacy policy. 

9 ‘‘(D) Office officials responsible for data 

10 governance. 

11 ‘‘(E) The appropriate congressional com12 mittees. 

13 ‘‘(F) Any other individual or entity as de14 termined by the Director. 

15 ‘‘(c) EVIDENCE-BASED POLICY.— 

16 ‘‘(1) HARM REDUCTION PROGRAMS.—When de17 veloping the national drug control policy, any policy 

18 of the Director, including policies relating to syringe 

19 exchange programs for intravenous drug users, shall 

20 be based on the best available medical and scientific 

21 evidence regarding the effectiveness of such policy in 

22 promoting individual health, preventing the spread of 

23 infectious disease and the impact of such policy on 

24 drug addiction and use. In making any policy relat25 ing to harm reduction programs, the Director shall 


pbinns on DSK79D2C42PROD with BILLS
100 

•HR 5925 RH

1 consult with the National Institutes of Health and the 

2 National Academy of Sciences. 

3 ‘‘(2) FUND RESTRICTION FOR THE LEGALIZATION

4 OF CONTROLLED SUBSTANCES.—The Director shall 

5 ensure that no Federal funds appropriated to the Of6 fice shall be expended for any study or contract relat7 ing to the legalization (for a medical use or any other 

8 use) for which a listing in schedule I is in effect 

9 under section 202 of the Controlled Substances Act 

10 (21 U.S.C. 812). 

11 ‘‘(d) DRUG CONTROL DATA DASHBOARD.— 

12 ‘‘(1) ESTABLISHMENT.—The Director, in con13 sultation with the Center Director, shall establish and 

14 maintain a data dashboard on the online portal of 

15 the Office to be known as the ‘Drug Control Data 

16 Dashboard’. The Director shall ensure the user inter17 face of the dashboard is constructed with modern de18 sign standards. To the extent practicable, the data 

19 made available on the dashboard shall be publicly 

20 available in a machine-readable format and search21 able by year, agency, drug, and location. 

22 ‘‘(2) DATA.—The data included in the Drug 

23 Control Data Dashboard shall be updated not less fre24 quently than quarterly and shall include, at a min25 imum, the following: 


pbinns on DSK79D2C42PROD with BILLS
101 

•HR 5925 RH

1 ‘‘(A) For each substance identified under 

2 section 1005(c)(1)(A)(i)— 

3 ‘‘(i) the total amount seized and dis4 rupted in the calendar year and each of the 

5 previous 3 calendar years; 

6 ‘‘(ii) the known and estimated flows 

7 into the United States from all sources in 

8 the calendar year and each of the previous 

9 3 calendar years; 

10 ‘‘(iii) the total amount of known flows 

11 that could not be interdicted or disrupted in 

12 the calendar year and each of the previous 

13 3 calendar years; 

14 ‘‘(iv) the known and estimated levels of 

15 domestic production in the calendar year 

16 and each of the previous three calendar 

17 years, including the levels of domestic pro18 duction if the drug is a prescription drug, 

19 as determined under the Federal Food, 

20 Drug, and Cosmetic Act, for which a listing 

21 is in effect under section 202 of the Con22 trolled Substances Act (21 U.S.C. 812); and 

23 ‘‘(v) the average street price for the cal24 endar year and the highest known street 

25 price during the preceding 10-year period. 


pbinns on DSK79D2C42PROD with BILLS
102 

•HR 5925 RH

1 ‘‘(B) For the calendar year and each of the 

2 previous three years data sufficient to show, 

3 disaggregated by State and, to the extent feasible, 

4 by region within a State, county, or city, the fol5 lowing: 

6 ‘‘(i) The number of fatal and non-fatal 

7 overdoses caused by each drug identified 

8 under subparagraph (A)(i). 

9 ‘‘(ii) The prevalence of substance use 

10 disorders. 

11 ‘‘(iii) The number of individuals who 

12 have received substance use disorder treat13 ment, including medication assisted treat14 ment, for a substance use disorder, includ15 ing treatment provided through publicly-fi16 nanced health care programs. 

17 ‘‘(iv) The extent of the unmet need for 

18 substance use disorder treatment, including 

19 the unmet need for medication-assisted 

20 treatment. 

21 ‘‘(C) Data sufficient to show the extent of 

22 prescription drug diversion, trafficking, and 

23 misuse in the calendar year and each of the pre24 vious 3 calendar years. 


pbinns on DSK79D2C42PROD with BILLS
103 

•HR 5925 RH

1 ‘‘(D) Any quantifiable measures the Direc2 tor determines to be appropriate to detail 

3 progress toward the achievement of the goals of 

4 the National Drug Control Strategy. 

5 ‘‘(e) ACCESS TO INFORMATION.— 

6 ‘‘(1) IN GENERAL.—Upon the request of the Di7 rector, the head of any National Drug Control Pro8 gram Agency shall cooperate with and provide to the 

9 Director any statistics, studies, reports, and other in10 formation prepared or collected by the agency con11 cerning the responsibilities of the agency under the 

12 National Drug Control Strategy that relate to— 

13 ‘‘(A) drug control; or 

14 ‘‘(B) the manner in which amounts made 

15 available to that agency for drug control are 

16 being used by that agency. 

17 ‘‘(2) PROTECTION OF INTELLIGENCE INFORMA18 TION.— 

19 ‘‘(A) IN GENERAL.—The authorities con20 ferred on the Office and the Director by this 

21 chapter shall be exercised in a manner consistent 

22 with provisions of the National Security Act of 

23 1947 (50 U.S.C. 401 et seq.). The Director of Na24 tional Intelligence shall prescribe such regula25 tions as may be necessary to protect information 


pbinns on DSK79D2C42PROD with BILLS
104 

•HR 5925 RH

1 provided pursuant to this chapter regarding in2 telligence sources and methods. 

3 ‘‘(B) DUTIES OF DIRECTOR.—The Director 

4 of National Intelligence and the Director of the 

5 Central Intelligence Agency shall, to the max6 imum extent practicable in accordance with sub7 paragraph (A), render full assistance and sup8 port to the Office and the Director. 

9 ‘‘(3) REQUIRED REPORTS FROM NATIONAL DRUG

10 CONTROL AGENCIES.—The head of each National 

11 Drug Control Program Agency shall submit to the Di12 rector such information and reports as requested from 

13 such National Drug Control Program Agency by the 

14 Director, which shall include from the appropriate 

15 National Drug Control Program Agencies: 

16 ‘‘(A) Not later than July 1 of each year, the 

17 head of a designated National Drug Control Pro18 gram Agency shall submit to the Director and 

19 the appropriate congressional committees an as20 sessment of the quantity of illegal drug cultiva21 tion and manufacturing in the United States on 

22 lands owned or under the jurisdiction of their re23 spective agencies that was seized or eradicated by 

24 their personnel during the preceding calendar 

25 year. 


pbinns on DSK79D2C42PROD with BILLS
105 

•HR 5925 RH

1 ‘‘(B) Not later than July 1 of each year, the 

2 head of a designated National Drug Control Pro3 gram Agency shall submit to the Director and 

4 the appropriate congressional committees infor5 mation for the preceding year regarding— 

6 ‘‘(i) the number and type of seizures of 

7 drugs by each component of the agency seiz8 ing drugs, as well as statistical information 

9 on the geographic areas of such seizures; 

10 and 

11 ‘‘(ii) the number of air and maritime 

12 patrol hours primarily dedicated to drug 

13 supply reduction missions undertaken by 

14 each component of the agency. 

15 ‘‘(C) Not later than July 1 of each year, the 

16 head of a designated National Drug Control Pro17 gram Agency shall submit to the Director and 

18 the appropriate congressional committees infor19 mation for the preceding year regarding the 

20 number of air and maritime patrol hours pri21 marily dedicated to drug supply reduction mis22 sions undertaken by each component of the agen23 cy. 

24 ‘‘(D) Not later than July 1 of each year, the 

25 head of a designated National Drug Control ProVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00105 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
106 

•HR 5925 RH

1 gram Agency shall submit to the Director and 

2 the appropriate congressional committees infor3 mation for the preceding year regarding the 

4 number and type of— 

5 ‘‘(i) arrests for drug violations; 

6 ‘‘(ii) prosecutions for drug violations 

7 by United States Attorneys; and 

8 ‘‘(iii) seizures of drugs by each compo9 nent of the Department of Justice seizing 

10 drugs, as well as statistical information on 

11 the geographic areas of such seizures. 

12 ‘‘(f) DATA EXCHANGE STANDARDS FOR IMPROVED

13 INTEROPERABILITY.— 

14 ‘‘(1) INTERAGENCY AND INTERGOVERNMENTAL

15 DESIGNATION AND USE OF DATA EXCHANGE STAND16 ARDS WORKING GROUP.—The Director shall establish 

17 a working group of National Drug Control Program 

18 Agencies, State, local and Tribal government health 

19 and law enforcement agencies, and data governance 

20 experts to develop consensus data exchange standards 

21 for necessary categories of information that allow ef22 fective electronic exchange of information between 

23 States, between State agencies, between States and 

24 National Drug Control Program Agencies, and any 

25 other drug control relevant data exchange. 


pbinns on DSK79D2C42PROD with BILLS
107 

•HR 5925 RH

1 ‘‘(2) DATA EXCHANGE STANDARDS MUST BE NON2 PROPRIETARY AND INTEROPERABLE.—The data ex3 change standards designated under paragraph (1) 

4 shall, to the extent practicable, be nonproprietary and 

5 interoperable. 

6 ‘‘(3) OTHER REQUIREMENTS.—In designating 

7 data exchange standards under this subsection, the 

8 working group shall, to the extent practicable, incor9 porate— 

10 ‘‘(A) interoperable standards developed and 

11 maintained by an international voluntary con12 sensus standards body, as defined by the Office 

13 of Management and Budget; 

14 ‘‘(B) interoperable standards developed and 

15 maintained by intergovernmental partnerships; 

16 and 

17 ‘‘(C) interoperable standards developed and 

18 maintained by Federal entities with authority 

19 over contracting and financial assistance. 

20 ‘‘(4) DATA EXCHANGE STANDARDS FOR FEDERAL

21 REPORTING.— 

22 ‘‘(A) DESIGNATION.—The Director may, in 

23 consultation with the working group established 

24 under this section, National Drug Control Pro25 gram Agencies, and State, local, and Tribal govVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00107 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
108 

•HR 5925 RH

1 ernments, designate data exchange standards to 

2 govern Federal reporting and exchange require3 ments for National Drug Control Programs, as 

4 appropriate. 

5 ‘‘(B) REQUIREMENTS.—The data exchange 

6 reporting standards required by subparagraph 

7 (A) shall, to the extent practicable— 

8 ‘‘(i) incorporate a widely accepted, 

9 nonproprietary, searchable, machine-read10 able format; 

11 ‘‘(ii) be consistent with and implement 

12 applicable accounting principles; 

13 ‘‘(iii) be implemented in a manner 

14 that is cost-effective and improves program 

15 efficiency and effectiveness; and 

16 ‘‘(iv) be capable of being continually 

17 upgraded as necessary. 

18 ‘‘(C) INCORPORATION OF NONPROPRIETARY

19 STANDARDS.—In designating data exchange 

20 standards under this paragraph, the Director 

21 shall, to the extent practicable, incorporate exist22 ing nonproprietary standards. 

23 ‘‘(D) RULE OF CONSTRUCTION.—Nothing in 

24 this paragraph shall be construed to require a 

25 change to existing data exchange standards for 


pbinns on DSK79D2C42PROD with BILLS
109 

•HR 5925 RH

1 Federal reporting about a program referred to in 

2 this section, if the head of the agency responsible 

3 for administering the program finds the stand4 ards to be effective and efficient. 

5 ‘‘(5) TERMINATION.—The working group estab6 lished under paragraph (1) shall terminate not ear7 lier than 60 days after the public notification of ter8 mination by the Director. 

9 ‘‘(g) ANNUAL DATA COLLECTION AND DISSEMINATION

10 REQUIREMENTS.— 

11 ‘‘(1) IN GENERAL.—The Director shall collect 

12 and disseminate, as appropriate, such information as 

13 the Director determines is appropriate, but not less 

14 than the information described in this subsection. To 

15 the extent practicable, the data shall be publicly 

16 available in a machine-readable format on the Drug 

17 Control Data Dashboard, be searchable by year, agen18 cy, drug, and location, and cover not less than the 

19 previous 10-year period. 

20 ‘‘(2) PREPARATION AND DISSEMINATION OF IN21 FORMATION.—The Director shall prepare and dis22 seminate the following: 

23 ‘‘(A) An assessment of current illicit drug 

24 use (including inhalants and steroids) and availVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00109 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
110 

•HR 5925 RH

1 ability, impact of illicit drug use, and treatment 

2 availability, which assessment shall include— 

3 ‘‘(i) estimates of drug prevalence and 

4 frequency of use as measured by national, 

5 State, and local surveys of illicit drug use 

6 and by other special studies of non7 dependent and dependent illicit drug use; 

8 ‘‘(ii) illicit drug use in the workplace 

9 and the productivity lost by such use; and 

10 ‘‘(iii) illicit drug use by arrestees, pro11 bationers, and parolees. 

12 ‘‘(B) An assessment of the reduction of il13 licit drug availability, for each drug identified 

14 under section 1005(c)(1)(A)(i), as measured by— 

15 ‘‘(i) the quantities of such drug avail16 able for consumption in the United States; 

17 ‘‘(ii) the amount of such drug entering 

18 the United States; 

19 ‘‘(iii) the number of illicit drug manu20 facturing laboratories seized and destroyed 

21 of each relevant drug and the number of 

22 hectares cultivated and destroyed domesti23 cally and in other countries of each relevant 

24 drug; 


pbinns on DSK79D2C42PROD with BILLS
111 

•HR 5925 RH

1 ‘‘(iv) the number of metric tons of such 

2 drug seized; and 

3 ‘‘(v) changes in the price and purity of 

4 such drug. 

5 ‘‘(C) An assessment of the reduction of the 

6 consequences of illicit drug use and availability, 

7 which shall include— 

8 ‘‘(i) the cost of treating substance use 

9 disorder in the United States, such as the 

10 quantity of illicit drug-related services pro11 vided; 

12 ‘‘(ii) the annual national health care 

13 cost of illicit drug use; and 

14 ‘‘(iii) the extent of illicit drug-related 

15 crime and criminal activity. 

16 ‘‘(D) A determination of the status of drug 

17 treatment in the United States, by assessing— 

18 ‘‘(i) public and private treatment utili19 zation; and 

20 ‘‘(ii) the number of illicit drug users 

21 the Director estimates meet diagnostic cri22 teria for treatment. 

23 ‘‘(E) A summary of the efforts made to co24 ordinate with private sector entities to conduct 


pbinns on DSK79D2C42PROD with BILLS
112 

•HR 5925 RH

1 private research and development of medications 

2 to treat addiction by— 

3 ‘‘(i) screening chemicals for potential 

4 therapeutic value; 

5 ‘‘(ii) developing promising compounds; 

6 ‘‘(iii) conducting clinical trials; 

7 ‘‘(iv) seeking Food and Drug Adminis8 tration approval for drugs to treat addic9 tion; 

10 ‘‘(v) marketing the drug for the treat11 ment of addiction; 

12 ‘‘(vi) urging physicians to use the drug 

13 in the treatment of addiction; and 

14 ‘‘(vii) encouraging insurance compa15 nies to reimburse the cost of the drug for the 

16 treatment of addiction. 

17 ‘‘§ 1014. Annual audit and investigation requirements 

18 ‘‘(a) PERIODIC GOVERNMENT ACCOUNTABILITY OF19 FICE AUDITS OF PROGRAMS AND OPERATIONS.—Not later 

20 than December 31, 2019, and every 3 years thereafter, the 

21 Comptroller General shall— 

22 ‘‘(1) conduct and supervise an audit and inves23 tigation relating to the programs and operations of— 

24 ‘‘(A) the Office; or 


pbinns on DSK79D2C42PROD with BILLS
113 

•HR 5925 RH

1 ‘‘(B) certain programs within the Office, in2 cluding— 

3 ‘‘(i) the High Intensity Drug Traf4 ficking Areas Program; and 

5 ‘‘(iii) the media campaign under sec6 tion 1009(d); and 

7 ‘‘(2) submit to the Director and the appropriate 

8 congressional committees a report containing an eval9 uation of and recommendations on the— 

10 ‘‘(A) policies and activities of the programs 

11 and operations subject to the audit and inves12 tigation; 

13 ‘‘(B) economy, efficiency, and effectiveness 

14 in the administration of the reviewed programs 

15 and operations; and 

16 ‘‘(C) policy or management changes needed 

17 to prevent and detect fraud and abuse in such 

18 programs and operations. 

19 ‘‘§ 1015. Authorization of appropriations 

20 ‘‘There are authorized to be appropriated to carry out 

21 this chapter, except as otherwise specified, to remain avail22 able until expended, $18,400,000 for each of fiscal years 

23 2019 through 2023. 


pbinns on DSK79D2C42PROD with BILLS
114 

•HR 5925 RH

1 ‘‘SUBCHAPTER II—HIGH INTENSITY DRUG 

2 TRAFFICKING AREAS PROGRAM 

3 ‘‘§ 1021. High intensity drug trafficking areas pro4 gram 

5 ‘‘(a) ESTABLISHMENT.— 

6 ‘‘(1) IN GENERAL.—There is established in the 

7 Office a program to be known as the High Intensity 

8 Drug Trafficking Areas Program (in this section re9 ferred to as the ‘Program’). 

10 ‘‘(2) PURPOSE.—The purpose of the Program is 

11 to reduce drug trafficking and drug production in the 

12 United States by— 

13 ‘‘(A) facilitating cooperation among Fed14 eral, State, local, and Tribal law enforcement 

15 agencies to share information and implement co16 ordinated enforcement activities; 

17 ‘‘(B) enhancing law enforcement intelligence 

18 sharing among Federal, State, local, and Tribal 

19 law enforcement agencies; 

20 ‘‘(C) providing reliable law enforcement in21 telligence to law enforcement agencies needed to 

22 design effective enforcement strategies and oper23 ations; and 

24 ‘‘(D) supporting coordinated law enforce25 ment strategies which maximize use of available 


pbinns on DSK79D2C42PROD with BILLS
115 

•HR 5925 RH

1 resources to reduce the supply of illegal drugs in 

2 designated areas and in the United States as a 

3 whole. 

4 ‘‘(b) DESIGNATION.— 

5 ‘‘(1) IN GENERAL.—The Director, in consultation 

6 with the Attorney General, the Secretary of the Treas7 ury, the Secretary of Homeland Security, heads of the 

8 National Drug Control Program Agencies, and the 

9 Governor of each applicable State, may designate any 

10 specified area of the United States as a high intensity 

11 drug trafficking area. 

12 ‘‘(2) ACTIVITIES.—After making a designation 

13 under paragraph (1) and in order to provide Federal 

14 assistance to the area so designated, the Director 

15 may— 

16 ‘‘(A) obligate such sums as are appropriated 

17 for the Program; 

18 ‘‘(B) direct the temporary reassignment of 

19 Federal personnel to such area, subject to the ap20 proval of the head of the agency that employs 

21 such personnel; 

22 ‘‘(C) take any other action authorized under 

23 this chapter to provide increased Federal assist24 ance to those areas; and 


pbinns on DSK79D2C42PROD with BILLS
116 

•HR 5925 RH

1 ‘‘(D) coordinate activities under this section 

2 (specifically administrative, recordkeeping, and 

3 funds management activities) with State, local, 

4 and Tribal officials. 

5 ‘‘(c) PETITIONS FOR DESIGNATION.—The Director 

6 shall establish and maintain regulations under which a coa7 lition of interested law enforcement agencies from an area 

8 may petition for designation as a high intensity drug traf9 ficking area (in this section referred to as the ‘HIDTA’). 

10 Such regulations shall provide for a regular review by the 

11 Director of the petition, including a recommendation re12 garding the merit of the petition to the Director by a panel 

13 of qualified, independent experts. 

14 ‘‘(d) FACTORS FOR CONSIDERATION.—In considering 

15 whether to designate an area under this section as a high 

16 intensity drug trafficking area, the Director shall consider, 

17 in addition to such other criteria as the Director considers 

18 to be appropriate, the extent to which— 

19 ‘‘(1) the area is a significant center of illegal 

20 drug production, manufacturing, importation, or dis21 tribution; 

22 ‘‘(2) State, local, and Tribal law enforcement 

23 agencies have committed resources to respond to the 

24 drug trafficking problem in the area, thereby indiVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00116 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
117 

•HR 5925 RH

1 cating a determination to respond aggressively to the 

2 problem; 

3 ‘‘(3) drug-related activities in the area are hav4 ing a significant harmful impact in the area, and in 

5 other areas of the country; and 

6 ‘‘(4) a significant increase in allocation of Fed7 eral resources is necessary to respond adequately to 

8 drug-related activities in the area. 

9 ‘‘(e) ORGANIZATION OF HIGH INTENSITY DRUG TRAF10 FICKING AREAS.— 

11 ‘‘(1) EXECUTIVE BOARD AND OFFICERS.—To be 

12 eligible for funds appropriated under this section, 

13 each high intensity drug trafficking area shall be gov14 erned by an Executive Board. The Executive Board 

15 shall designate a chairman, vice chairman, and any 

16 other officers to the Executive Board that it deter17 mines are necessary. 

18 ‘‘(2) RESPONSIBILITIES.—The Executive Board 

19 of a high intensity drug trafficking area shall be re20 sponsible for— 

21 ‘‘(A) providing direction and oversight in 

22 establishing and achieving the goals of the high 

23 intensity drug trafficking area; 

24 ‘‘(B) managing the funds of the high inten25 sity drug trafficking area; 


pbinns on DSK79D2C42PROD with BILLS
118 

•HR 5925 RH

1 ‘‘(C) reviewing and approving all funding 

2 proposals consistent with the overall objective of 

3 the high intensity drug trafficking area; and 

4 ‘‘(D) reviewing and approving all reports to 

5 the Director on the activities of the high inten6 sity drug trafficking area. 

7 ‘‘(3) BOARD REPRESENTATION.—None of the 

8 funds appropriated under this section may be ex9 pended for any high intensity drug trafficking area, 

10 or for a partnership or region of a high intensity 

11 drug trafficking area, if the Executive Board for such 

12 area, region, or partnership, does not apportion an 

13 equal number of votes between representatives of par14 ticipating agencies and representatives of partici15 pating State, local, and Tribal agencies. Where it is 

16 impractical for an equal number of representatives of 

17 agencies and State, local, and Tribal agencies to at18 tend a meeting of an Executive Board in person, the 

19 Executive Board may use a system of proxy votes or 

20 weighted votes to achieve the voting balance required 

21 by this paragraph. 

22 ‘‘(4) NO AGENCY RELATIONSHIP.—The eligibility 

23 requirements of this section are intended to ensure the 

24 responsible use of Federal funds. Nothing in this sec25 tion is intended to create an agency relationship beVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00118 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
119 

•HR 5925 RH

1 tween individual high intensity drug trafficking areas 

2 and the Federal Government. 

3 ‘‘(f) USE OF FUNDS.—The Director shall ensure that 

4 not more than 5 percent of Federal funds appropriated for 

5 the Program are expended for drug treatment programs and 

6 not more than 5 percent of the Federal funds appropriated 

7 for the Program are expended for drug prevention pro8 grams. 

9 ‘‘(g) COUNTERTERRORISM ACTIVITIES.— 

10 ‘‘(1) ASSISTANCE AUTHORIZED.—The Director 

11 may authorize use of resources available for the Pro12 gram to assist Federal, State, local, and Tribal law 

13 enforcement agencies in investigations and activities 

14 related to terrorism and prevention of terrorism, espe15 cially but not exclusively with respect to such inves16 tigations and activities that are also related to drug 

17 trafficking. 

18 ‘‘(2) LIMITATION.—The Director shall ensure— 

19 ‘‘(A) that assistance provided under para20 graph (1) remains incidental to the purpose of 

21 the Program to reduce drug availability and 

22 carry out drug-related law enforcement activi23 ties; and 

24 ‘‘(B) that significant resources of the Pro25 gram are not redirected to activities exclusively 


pbinns on DSK79D2C42PROD with BILLS
120 

•HR 5925 RH

1 related to terrorism, except on a temporary basis 

2 under extraordinary circumstances, as deter3 mined by the Director. 

4 ‘‘(h) ROLE OF DRUG ENFORCEMENT ADMINISTRA5 TION.—The Director, in consultation with the Attorney 

6 General, shall ensure that a representative of the Drug En7 forcement Administration is included in the Intelligence 

8 Support Center for each high intensity drug trafficking 

9 area. 

10 ‘‘(i) EMERGING THREAT RESPONSE FUND.— 

11 ‘‘(1) IN GENERAL.—Subject to the availability of 

12 appropriations, the Director may expend up to 10 

13 percent of the amounts appropriated under this sec14 tion on a discretionary basis, in accordance with the 

15 criteria established under paragraph (2)— 

16 ‘‘(A) to respond to any emerging drug traf17 ficking threat in an existing high intensity drug 

18 trafficking area; 

19 ‘‘(B) to establish a new high intensity drug 

20 trafficking area; or 

21 ‘‘(C) to expand an existing high intensity 

22 drug trafficking area. 

23 ‘‘(2) CONSIDERATION OF IMPACT.—In allocating 

24 funds under this subsection, the Director shall con25 sider— 


pbinns on DSK79D2C42PROD with BILLS
121 

•HR 5925 RH

1 ‘‘(A) the impact of activities funded on re2 ducing overall drug traffic in the United States, 

3 or minimizing the probability that an emerging 

4 drug trafficking threat will spread to other areas 

5 of the United States; and 

6 ‘‘(B) such other criteria as the Director con7 siders appropriate. 

8 ‘‘(j) ANNUAL HIDTA PROGRAM BUDGET SUBMIS9 SIONS.—As part of the documentation that supports the 

10 President’s annual budget request for the Office, the Direc11 tor shall submit to Congress a budget justification that in12 cludes— 

13 ‘‘(1) the amount proposed for each HIDTA, con14 ditional upon a review by the Office of the request 

15 submitted by such HIDTA and the performance of 

16 such HIDTA, with supporting narrative descriptions 

17 and rationale for each request; 

18 ‘‘(2) a detailed justification that explains— 

19 ‘‘(A) the reasons for the proposed funding 

20 level and how such funding level was determined 

21 based on a current assessment of the drug traf22 ficking threat in each high intensity drug traf23 ficking area; 


pbinns on DSK79D2C42PROD with BILLS
122 

•HR 5925 RH

1 ‘‘(B) how such funding will ensure that the 

2 goals and objectives of each such area will be 

3 achieved; and 

4 ‘‘(C) how such funding supports the Na5 tional Drug Control Strategy; and 

6 ‘‘(3) the amount of HIDTA funds used to inves7 tigate and prosecute organizations and individuals 

8 trafficking in each major illicit drug, as identified by 

9 the Director, in the prior calendar year, and a de10 scription of how those funds were used. 

11 ‘‘(k) HIDTA ANNUAL EVALUATION REPORT.—As part 

12 of each National Drug Control Evaluation assessment 

13 under section 1006, the Director shall include, for each des14 ignated high intensity drug trafficking area, a report 

15 that— 

16 ‘‘(1) describes— 

17 ‘‘(A) the specific purposes for the high in18 tensity drug trafficking area; and 

19 ‘‘(B) the specific long-term and short-term 

20 goals and objectives for the high intensity drug 

21 trafficking area; 

22 ‘‘(2) includes an evaluation of the performance of 

23 the high intensity drug trafficking area in accom24 plishing the specific long-term and short-term goals 

25 and objectives identified under subparagraph (1)(B); 


pbinns on DSK79D2C42PROD with BILLS
123 

•HR 5925 RH

1 ‘‘(3) assesses the number and operation of all fed2 erally funded drug enforcement task forces within 

3 such high intensity drug trafficking area; 

4 ‘‘(4) describes— 

5 ‘‘(A) each Federal, State, local, and Tribal 

6 drug enforcement task force operating in such 

7 high intensity drug trafficking area; 

8 ‘‘(B) how such task forces coordinate with 

9 each other, with any high intensity drug traf10 ficking area task force, and with investigations 

11 receiving funds from the Organized Crime and 

12 Drug Enforcement Task Force; 

13 ‘‘(C) what steps, if any, each such task force 

14 takes to share information regarding drug traf15 ficking and drug production with other federally 

16 funded drug enforcement task forces in the high 

17 intensity drug trafficking area; 

18 ‘‘(D) the role of the high intensity drug traf19 ficking area in coordinating the sharing of such 

20 information among task forces; 

21 ‘‘(E) the nature and extent of cooperation 

22 by each Federal, State, local, and Tribal partici23 pant in ensuring that such information is shared 

24 among law enforcement agencies and with the 

25 high intensity drug trafficking area; 


pbinns on DSK79D2C42PROD with BILLS
124 

•HR 5925 RH

1 ‘‘(F) the nature and extent to which infor2 mation sharing and enforcement activities are 

3 coordinated with joint terrorism task forces in 

4 the high intensity drug trafficking area; and 

5 ‘‘(G) any recommendations for measures 

6 needed to ensure that task force resources are uti7 lized efficiently and effectively to reduce the 

8 availability of illegal drugs in the high intensity 

9 drug trafficking areas; and 

10 ‘‘(5) in consultation with the Director of Na11 tional Intelligence— 

12 ‘‘(A) evaluates existing and planned law en13 forcement intelligence systems supported by such 

14 high intensity drug trafficking area, or utilized 

15 by task forces receiving any funding under the 

16 Program, including the extent to which such sys17 tems ensure access and availability of law en18 forcement intelligence to Federal, State, local, 

19 and Tribal law enforcement agencies within the 

20 high intensity drug trafficking area and outside 

21 of such area; 

22 ‘‘(B) evaluates the extent to which Federal, 

23 State, local, and Tribal law enforcement agencies 

24 participating in each high intensity drug traf25 ficking area are sharing law enforcement intelVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00124 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
125 

•HR 5925 RH

1 ligence information to assess current drug traf2 ficking threats and design appropriate enforce3 ment strategies; and 

4 ‘‘(C) identifies the measures needed to im5 prove effective sharing of information and law 

6 enforcement intelligence regarding drug traf7 ficking and drug production among Federal, 

8 State, local, and Tribal law enforcement partici9 pating in a high intensity drug trafficking area, 

10 and between such agencies and similar agencies 

11 outside the high intensity drug trafficking area. 

12 ‘‘(l) COORDINATION OF LAW ENFORCEMENT INTEL13 LIGENCE SHARING WITH ORGANIZED CRIME DRUG EN14 FORCEMENT TASK FORCE PROGRAM.— 

15 ‘‘(1) DRUG ENFORCEMENT INTELLIGENCE SHAR16 ING.—The Director, in consultation with the Attorney 

17 General, shall ensure that any drug enforcement intel18 ligence obtained by the Intelligence Support Center 

19 for each high intensity drug trafficking area is 

20 shared, on a timely basis, with the drug intelligence 

21 fusion center operated by the Organized Crime Drug 

22 Enforcement Task Force of the Department of Justice. 

23 ‘‘(2) CERTIFICATION.—Before the Director 

24 awards any funds to a high intensity drug trafficking 

25 area, the Director shall certify that the law enforceVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00125 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
126 

•HR 5925 RH

1 ment entities participating in that HIDTA are pro2 viding laboratory seizure data to the national clan3 destine laboratory database at the El Paso Intel4 ligence Center. 

5 ‘‘(m) AUTHORIZATION OF APPROPRIATIONS.—There is 

6 authorized to be appropriated to the Office to carry out this 

7 section $280,000,000 for each fiscal years 2019 through 

8 2023. 

9 ‘‘(n) SPECIFIC PURPOSES.— 

10 ‘‘(1) IN GENERAL.—The Director shall ensure 

11 that, of the amounts appropriated for a fiscal year for 

12 the Program, at least 2.5 percent is used in high in13 tensity drug trafficking areas with severe neighbor14 hood safety and illegal drug distribution problems. 

15 ‘‘(2) REQUIRED USES.—The funds used under 

16 paragraph (1) shall be used to ensure the safety of 

17 neighborhoods and the protection of communities, in18 cluding the prevention of the intimidation of wit19 nesses of illegal drug distribution and related activi20 ties and the establishment of or support for programs 

21 that provide protection or assistance to witnesses in 

22 court proceedings. 

23 ‘‘(3) BEST PRACTICE MODELS.—The Director 

24 shall work with the HIDTAs to develop and maintain 

25 best practice models to assist State, local, and Tribal 


pbinns on DSK79D2C42PROD with BILLS
127 

•HR 5925 RH

1 governments in addressing witness safety, relocation, 

2 financial and housing assistance, or any other serv3 ices related to witness protection or assistance in 

4 cases of illegal drug distribution and related activi5 ties. The Director shall ensure dissemination of the 

6 best practice models to each HIDTA. 

7 ‘‘SUBCHAPTER III—DRUG-FREE COMMUNITIES 

8 SUPPORT PROGRAM 

9 ‘‘§ 1031. Establishment of drug-free communities sup10 port program 

11 ‘‘(a) ESTABLISHMENT.—The Director shall establish a 

12 program to support communities in the development and 

13 implementation of comprehensive, long-term plans and pro14 grams to prevent and treat substance use and misuse among 

15 youth. 

16 ‘‘(b) PROGRAM.—In carrying out the Program, the Di17 rector shall— 

18 ‘‘(1) make and track grants to grant recipients; 

19 ‘‘(2) provide for technical assistance and train20 ing, data collection, and dissemination of information 

21 on state-of-the-art practices that the Director deter22 mines to be effective in reducing substance use; and 

23 ‘‘(3) provide for the general administration of 

24 the Program. 


pbinns on DSK79D2C42PROD with BILLS
128 

•HR 5925 RH

1 ‘‘(c) ADMINISTRATION.—The Director shall appoint an 

2 Administrator to carry out the Program. 

3 ‘‘(d) CONTRACTING.—The Director may employ any 

4 necessary staff and may enter into contracts or agreements 

5 with national drug control agencies, including interagency 

6 agreements, to delegate authority for the execution of grants 

7 and for such other activities necessary to carry out this 

8 chapter. 

9 ‘‘§ 1032. Program authorization 

10 ‘‘(a) GRANT ELIGIBILITY.—To be eligible to receive an 

11 initial grant or a renewal grant under this subchapter, a 

12 coalition shall meet each of the following criteria: 

13 ‘‘(1) APPLICATION.—The coalition shall submit 

14 an application to the Administrator in accordance 

15 with section 1033(a)(2). 

16 ‘‘(2) MAJOR SECTOR INVOLVEMENT.— 

17 ‘‘(A) IN GENERAL.—The coalition shall con18 sist of 1 or more representatives of each of the 

19 following categories: 

20 ‘‘(i) Youth. 

21 ‘‘(ii) Parents. 

22 ‘‘(iii) Businesses. 

23 ‘‘(iv) The media. 

24 ‘‘(v) Schools. 

25 ‘‘(vi) Organizations serving youth. 


pbinns on DSK79D2C42PROD with BILLS
129 

•HR 5925 RH

1 ‘‘(vii) Law enforcement. 

2 ‘‘(viii) Religious or fraternal organiza3 tions. 

4 ‘‘(ix) Civic and volunteer groups. 

5 ‘‘(x) Health care professionals. 

6 ‘‘(xi) State, local, or tribal govern7 mental agencies with expertise in the field 

8 of substance use prevention or substance use 

9 disorders (including, if applicable, the State 

10 authority with primary authority for sub11 stance use and misuse). 

12 ‘‘(xii) Other organizations involved in 

13 reducing the prevalence of substance use and 

14 misuse or substance use disorders. 

15 ‘‘(B) ELECTED OFFICIALS.—If feasible, in 

16 addition to representatives from the categories 

17 listed in subparagraph (A), the coalition shall 

18 have an elected official (or a representative of an 

19 elected official) from— 

20 ‘‘(i) the Federal Government; and 

21 ‘‘(ii) the government of the appropriate 

22 State and political subdivision thereof or 

23 the governing body or an Indian tribe (as 

24 that term is defined in section 4(e) of the 


pbinns on DSK79D2C42PROD with BILLS
130 

•HR 5925 RH

1 Indian Self-Determination Act (25 U.S.C. 

2 450b(e))). 

3 ‘‘(C) REPRESENTATION.—An individual 

4 who is a member of the coalition may serve on 

5 the coalition as a representative of not more than 

6 1 category listed under subparagraph (A). 

7 ‘‘(3) COMMITMENT.—The coalition shall dem8 onstrate, to the satisfaction of the Administrator— 

9 ‘‘(A) that the representatives of the coalition 

10 have worked together on substance use and mis11 use reduction initiatives, which, at a minimum, 

12 includes initiatives that target drugs described in 

13 section 1037(6)(A), for a period of not less than 

14 6 months, acting through entities such as task 

15 forces, subcommittees, or community boards; and 

16 ‘‘(B) substantial participation from volun17 teer leaders in the community involved (espe18 cially in cooperation with individuals involved 

19 with youth such as parents, teachers, coaches, 

20 youth workers, and members of the clergy). 

21 ‘‘(4) MISSION AND STRATEGIES.—The coalition 

22 shall, with respect to the community involved— 

23 ‘‘(A) have as its principal mission the re24 duction of illegal drug use, which, at a min25 imum, includes the use of illegal drugs described 


pbinns on DSK79D2C42PROD with BILLS
131 

•HR 5925 RH

1 in section 1037(6)(A), in a comprehensive and 

2 long-term manner, with a primary focus on 

3 youth in the community; 

4 ‘‘(B) describe and document the nature and 

5 extent of the substance use and misuse problem, 

6 which, at a minimum, includes the use and mis7 use of drugs described in section 1037(6)(A), in 

8 the community; 

9 ‘‘(C)(i) provide a description of substance 

10 use and misuse prevention and treatment pro11 grams and activities, which, at a minimum, in12 cludes programs and activities relating to the use 

13 and misuse of drugs described in section 

14 1037(6)(A), in existence at the time of the grant 

15 application; and 

16 ‘‘(ii) identify substance use and misuse pro17 grams and service gaps, which, at a minimum, 

18 includes programs and gaps relating to the use 

19 and misuse of drugs described in section 

20 1037(6)(A), in the community; 

21 ‘‘(D) develop a strategic plan to reduce sub22 stance use and misuse among youth, which, at a 

23 minimum, includes the use and misuse of drugs 

24 described in section 1037(6)(A), in a comprehen25 sive and long-term fashion; and 


pbinns on DSK79D2C42PROD with BILLS
132 

•HR 5925 RH

1 ‘‘(E) work to develop a consensus regarding 

2 the priorities of the community to combat sub3 stance use and misuse among youth, which, at a 

4 minimum, includes the use and misuse of drugs 

5 described in section 1037(6)(A). 

6 ‘‘(5) SUSTAINABILITY.—The coalition shall dem7 onstrate that the coalition is an ongoing concern by 

8 demonstrating that the coalition— 

9 ‘‘(A) is— 

10 ‘‘(i)(I) a nonprofit organization; or 

11 ‘‘(II) an entity that the Administrator 

12 determines to be appropriate; or 

13 ‘‘(ii) part of, or is associated with, an 

14 established legal entity; 

15 ‘‘(B) receives financial support (including, 

16 in the discretion of the Administrator, in-kind 

17 contributions) from non-Federal sources; and 

18 ‘‘(C) has a strategy to solicit substantial fi19 nancial support from non-Federal sources to en20 sure that the coalition and the programs oper21 ated by the coalition are self-sustaining. 

22 ‘‘(6) ACCOUNTABILITY.—The coalition shall— 

23 ‘‘(A) establish a system to measure and re24 port outcomes— 


pbinns on DSK79D2C42PROD with BILLS
133 

•HR 5925 RH

1 ‘‘(i) consistent with common indicators 

2 and evaluation protocols established by the 

3 Administrator; and 

4 ‘‘(ii) approved by the Administrator; 

5 ‘‘(B) conduct— 

6 ‘‘(i) for an initial grant under this 

7 subchapter, an initial benchmark survey of 

8 drug use among youth (or use local surveys 

9 or performance measures available or acces10 sible in the community at the time of the 

11 grant application); and 

12 ‘‘(ii) biennial surveys (or incorporate 

13 local surveys in existence at the time of the 

14 evaluation) to measure the progress and ef15 fectiveness of the coalition; and 

16 ‘‘(C) provide assurances that the entity con17 ducting an evaluation under this paragraph, or 

18 from which the coalition receives information, 

19 has experience— 

20 ‘‘(i) in gathering data related to sub21 stance use and misuse among youth; or 

22 ‘‘(ii) in evaluating the effectiveness of 

23 community anti-drug coalitions. 


pbinns on DSK79D2C42PROD with BILLS
134 

•HR 5925 RH

1 ‘‘(7) ADDITIONAL CRITERIA.—The Director shall 

2 not impose any eligibility criteria on new applicants 

3 or renewal grantees not provided in this chapter. 

4 ‘‘(b) GRANT AMOUNTS.— 

5 ‘‘(1) IN GENERAL.— 

6 ‘‘(A) GRANTS.— 

7 ‘‘(i) IN GENERAL.—Subject to clause 

8 (iv), for a fiscal year, the Administrator 

9 may grant to an eligible coalition under 

10 this paragraph, an amount not to exceed the 

11 amount of non-Federal funds raised by the 

12 coalition, including in-kind contributions, 

13 for that fiscal year. 

14 ‘‘(ii) SUSPENSION OF GRANTS.—If such 

15 grant recipient fails to continue to meet the 

16 criteria specified in subsection (a), the Ad17 ministrator may suspend the grant, after 

18 providing written notice to the grant recipi19 ent and an opportunity to appeal. 

20 ‘‘(iii) RENEWAL GRANTS.—Subject to 

21 clause (iv), the Administrator may award a 

22 renewal grant to a grant recipient under 

23 this subparagraph for each fiscal year fol24 lowing the fiscal year for which an initial 

25 grant is awarded, in an amount not to exVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00134 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
135 

•HR 5925 RH

1 ceed the amount of non-Federal funds raised 

2 by the coalition, including in-kind contribu3 tions, for that fiscal year, during the 4-year 

4 period following the period of the initial 

5 grant. 

6 ‘‘(iv) LIMITATION.—The amount of a 

7 grant award under this subparagraph may 

8 not exceed $125,000 for a fiscal year. 

9 ‘‘(B) COALITION AWARDS.— 

10 ‘‘(i) IN GENERAL.—Except as provided 

11 in clause (ii), the Administrator may, with 

12 respect to a community, make a grant to 1 

13 eligible coalition that represents that com14 munity. 

15 ‘‘(ii) EXCEPTION.—The Administrator 

16 may make a grant to more than 1 eligible 

17 coalition that represents a community if— 

18 ‘‘(I) the eligible coalitions dem19 onstrate that the coalitions are collabo20 rating with one another; and 

21 ‘‘(II) each of the coalitions has 

22 independently met the requirements set 

23 forth in subsection (a). 

24 ‘‘(2) RURAL COALITION GRANTS.— 

25 ‘‘(A) IN GENERAL.— 


pbinns on DSK79D2C42PROD with BILLS
136 

•HR 5925 RH

1 ‘‘(i) IN GENERAL.—In addition to 

2 awarding grants under paragraph (1), to 

3 stimulate the development of coalitions in 

4 sparsely populated and rural areas, the Ad5 ministrator may award a grant in accord6 ance with this section to a coalition that 

7 represents a county with a population that 

8 does not exceed 30,000 individuals. In 

9 awarding a grant under this paragraph, the 

10 Administrator may waive any requirement 

11 under subsection (a) if the Administrator 

12 considers that waiver to be appropriate. 

13 ‘‘(ii) MATCHING REQUIREMENT.—Sub14 ject to subparagraph (C), for a fiscal year, 

15 the Administrator may grant to an eligible 

16 coalition under this paragraph, an amount 

17 not to exceed the amount of non-Federal 

18 funds raised by the coalition, including in19 kind contributions, for that fiscal year. 

20 ‘‘(iii) SUSPENSION OF GRANTS.—If 

21 such grant recipient fails to continue to 

22 meet any criteria specified in subsection (a) 

23 that has not been waived by the Adminis24 trator pursuant to clause (i), the Adminis25 trator may suspend the grant, after proVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00136 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
137 

•HR 5925 RH

1 viding written notice to the grant recipient 

2 and an opportunity to appeal. 

3 ‘‘(B) RENEWAL GRANTS.—The Adminis4 trator may award a renewal grant to an eligible 

5 coalition that is a grant recipient under this 

6 paragraph for each fiscal year following the fis7 cal year for which an initial grant is awarded, 

8 in an amount not to exceed the amount of non9 Federal funds raised by the coalition, including 

10 in-kind contributions, during the 4-year period 

11 following the period of the initial grant. 

12 ‘‘(C) LIMITATIONS.— 

13 ‘‘(i) AMOUNT.—The amount of a grant 

14 award under this paragraph shall not ex15 ceed $125,000 for a fiscal year. 

16 ‘‘(ii) AWARDS.—With respect to a 

17 county referred to in subparagraph (A), the 

18 Administrator may award a grant under 

19 this section to not more than 1 eligible coa20 lition that represents the county. 

21 ‘‘(3) ADDITIONAL GRANTS.— 

22 ‘‘(A) IN GENERAL.—Subject to subpara23 graph (F), the Administrator may award an ad24 ditional grant under this paragraph to an eligi25 ble coalition awarded a grant under paragraph 


pbinns on DSK79D2C42PROD with BILLS
138 

•HR 5925 RH

1 (1) or (2) for any first fiscal year after the end 

2 of the 4-year period following the period of the 

3 initial grant under paragraph (1) or (2), as the 

4 case may be. 

5 ‘‘(B) SCOPE OF GRANTS.—A coalition 

6 awarded a grant under paragraph (1) or (2), in7 cluding a renewal grant under such paragraph, 

8 may not be awarded another grant under such 

9 paragraph, and is eligible for an additional 

10 grant under this section only under this para11 graph. 

12 ‘‘(C) NO PRIORITY FOR APPLICATIONS.—The 

13 Administrator may not afford a higher priority 

14 in the award of an additional grant under this 

15 paragraph than the Administrator would afford 

16 the applicant for the grant if the applicant were 

17 submitting an application for an initial grant 

18 under paragraph (1) or (2) rather than an ap19 plication for a grant under this paragraph. 

20 ‘‘(D) RENEWAL GRANTS.—Subject to sub21 paragraph (F), the Administrator may award a 

22 renewal grant to a grant recipient under this 

23 paragraph for each of the fiscal years of the 4- 

24 fiscal-year period following the fiscal year for 

25 which the initial additional grant under subVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00138 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
139 

•HR 5925 RH

1 paragraph (A) is awarded in an amount not to 

2 exceed amounts as follows: 

3 ‘‘(i) For the first and second fiscal 

4 years of that 4-fiscal-year period, the 

5 amount equal to 80 percent of the non-Fed6 eral funds, including in-kind contributions, 

7 raised by the coalition for the applicable fis8 cal year. 

9 ‘‘(ii) For the third and fourth fiscal 

10 years of that 4-fiscal-year period, the 

11 amount equal to 67 percent of the non-Fed12 eral funds, including in-kind contributions, 

13 raised by the coalition for the applicable fis14 cal year. 

15 ‘‘(E) SUSPENSION.—If a grant recipient 

16 under this paragraph fails to continue to meet 

17 the criteria specified in subsection (a), the Ad18 ministrator may suspend the grant, after pro19 viding written notice to the grant recipient and 

20 an opportunity to appeal. 

21 ‘‘(F) LIMITATION.—The amount of a grant 

22 award under this paragraph may not exceed 

23 $125,000 for a fiscal year. 

24 ‘‘(4) PROCESS FOR SUSPENSION.—A grantee 

25 shall not be suspended or terminated under paraVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00139 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
140 

•HR 5925 RH

1 graph (1)(A)(ii), (2)(A)(iii), or (3)(C) unless that 

2 grantee is afforded a fair, timely, and independent 

3 appeal prior to such suspension or termination. 

4 ‘‘(c) TREATMENT OF FUNDS FOR COALITIONS REP5 RESENTING CERTAIN ORGANIZATIONS.—Funds appro6 priated for the substance use and misuse activities of a coa7 lition that includes a representative of the Bureau of Indian 

8 Affairs, the Indian Health Service, or a tribal government 

9 agency with expertise in the field of substance use preven10 tion may be counted as non-Federal funds raised by the 

11 coalition for purposes of this section. 

12 ‘‘(d) PRIORITY IN AWARDING GRANTS.—In awarding 

13 grants under subsection (b)(1)(A)(i), priority shall be given 

14 to a coalition serving economically disadvantaged areas. 

15 ‘‘§ 1033. Information collection and dissemination 

16 with respect to grant recipients 

17 ‘‘(a) COALITION INFORMATION.— 

18 ‘‘(1) GENERAL AUDITING AUTHORITY.—For the 

19 purpose of audit and examination, the Adminis20 trator— 

21 ‘‘(A) shall have access to any books, docu22 ments, papers, and records that are pertinent to 

23 any grant or grant renewal request under this 

24 chapter; and 


pbinns on DSK79D2C42PROD with BILLS
141 

•HR 5925 RH

1 ‘‘(B) may periodically request information 

2 from a grant recipient to ensure that the grant 

3 recipient meets the applicable criteria under sec4 tion 1032(a). 

5 ‘‘(2) APPLICATION PROCESS.—The Administrator 

6 shall issue a request for proposal regarding, with re7 spect to the grants awarded under section 1032, the 

8 application process, grant renewal, and suspension or 

9 withholding of renewal grants. Each application 

10 under this paragraph shall be in writing and shall be 

11 subject to review by the Administrator. 

12 ‘‘(3) REPORTING.—The Administrator shall, to 

13 the maximum extent practicable and in a manner 

14 consistent with applicable law, minimize reporting 

15 requirements by a grant recipient and expedite any 

16 application for a renewal grant made under this sub17 chapter. 

18 ‘‘(b) DATA COLLECTION AND DISSEMINATION.— 

19 ‘‘(1) IN GENERAL.—The Administrator may col20 lect data from— 

21 ‘‘(A) national substance use and misuse or22 ganizations that work with eligible coalitions, 

23 community anti-drug coalitions, departments or 

24 agencies of the Federal Government, or State or 


pbinns on DSK79D2C42PROD with BILLS
142 

•HR 5925 RH

1 local governments and the governing bodies of 

2 Indian tribes; and 

3 ‘‘(B) any other entity or organization that 

4 carries out activities that relate to the purposes 

5 of the Program. 

6 ‘‘(2) ACTIVITIES OF ADMINISTRATOR.—The Ad7 ministrator may— 

8 ‘‘(A) evaluate the utility of specific initia9 tives relating to the purposes of the Program; 

10 ‘‘(B) conduct an evaluation of the Program; 

11 and 

12 ‘‘(C) disseminate information described in 

13 this subsection to— 

14 ‘‘(i) eligible coalitions and other sub15 stance use prevention organizations; and 

16 ‘‘(ii) the general public. 

17 ‘‘(3) CONSULTATION.—The Administrator shall 

18 carry out activities under this subsection in consulta19 tion with the National Community Antidrug Coali20 tion Institute. 

21 ‘‘(4) LIMITATION ON USE OF CERTAIN FUNDS

22 FOR EVALUATION OF PROGRAM.—Amounts for activi23 ties under paragraph (2)(B) may not be derived from 

24 amounts under section 1038(a) except for amounts 


pbinns on DSK79D2C42PROD with BILLS
143 

•HR 5925 RH

1 that are available under section 1038(b) for adminis2 trative costs. 

3 ‘‘§ 1034. Technical assistance and training 

4 ‘‘(a) IN GENERAL.— 

5 ‘‘(1) TECHNICAL ASSISTANCE AND AGREE6 MENTS.—With respect to any grant recipient or other 

7 organization, the Administrator may— 

8 ‘‘(A) offer technical assistance and training; 

9 and 

10 ‘‘(B) enter into contracts and cooperative 

11 agreements. 

12 ‘‘(2) COORDINATION OF PROGRAMS.—The Ad13 ministrator may facilitate the coordination of pro14 grams between a grant recipient and other organiza15 tions and entities. 

16 ‘‘(b) TRAINING.—The Administrator may provide 

17 training to any representative designated by a grant recipi18 ent in— 

19 ‘‘(1) coalition building; 

20 ‘‘(2) task force development; 

21 ‘‘(3) mediation and facilitation, direct service, 

22 assessment and evaluation; or 

23 ‘‘(4) any other activity related to the purposes of 

24 the Program. 


pbinns on DSK79D2C42PROD with BILLS
144 

•HR 5925 RH

1 ‘‘§ 1035. Supplemental grants for coalition mentoring 

2 activities 

3 ‘‘(a) AUTHORITY TO MAKE GRANTS.—As part of the 

4 program established under section 1031, the Director may 

5 award an initial grant under this subsection, and renewal 

6 grants under subsection (f), to any coalition awarded a 

7 grant under section 1032 that meets the criteria specified 

8 in subsection (d) in order to fund coalition mentoring ac9 tivities by such coalition in support of the program. 

10 ‘‘(b) TREATMENT WITH OTHER GRANTS.— 

11 ‘‘(1) SUPPLEMENT.—A grant awarded to a coali12 tion under this section is in addition to any grant 

13 awarded to the coalition under section 1032. 

14 ‘‘(2) REQUIREMENT FOR BASIC GRANT.—A coali15 tion may not be awarded a grant under this section 

16 for a fiscal year unless the coalition was awarded a 

17 grant or renewal grant under section 1032(b) for that 

18 fiscal year. 

19 ‘‘(c) APPLICATION.—A coalition seeking a grant under 

20 this section shall submit to the Administrator an applica21 tion for the grant in such form and manner as the Adminis22 trator may require. 

23 ‘‘(d) CRITERIA.—A coalition meets the criteria speci24 fied in this subsection if the coalition— 

25 ‘‘(1) has been in existence for at least 5 years; 


pbinns on DSK79D2C42PROD with BILLS
145 

•HR 5925 RH

1 ‘‘(2) has achieved, by or through its own efforts, 

2 measurable results in the prevention and treatment of 

3 substance use and misuse among youth; 

4 ‘‘(3) has staff or members willing to serve as 

5 mentors for persons seeking to start or expand the ac6 tivities of other coalitions in the prevention and treat7 ment of substance use and misuse; 

8 ‘‘(4) has demonstrable support from some mem9 bers of the community in which the coalition men10 toring activities to be supported by the grant under 

11 this section are to be carried out; and 

12 ‘‘(5) submits to the Administrator a detailed 

13 plan for the coalition mentoring activities to be sup14 ported by the grant under this section. 

15 ‘‘(e) USE OF GRANT FUNDS.—A coalition awarded a 

16 grant under this section shall use the grant amount for 

17 mentoring activities to support and encourage the develop18 ment of new, self-supporting community coalitions that are 

19 focused on the prevention and treatment of substance use 

20 and misuse in such new coalitions’ communities. The men21 toring coalition shall encourage such development in ac22 cordance with the plan submitted by the mentoring coali23 tion under subsection (d)(5). 

24 ‘‘(f) RENEWAL GRANTS.—The Administrator may 

25 make a renewal grant to any coalition awarded a grant 


pbinns on DSK79D2C42PROD with BILLS
146 

•HR 5925 RH

1 under subsection (a), or a previous renewal grant under 

2 this subsection, if the coalition, at the time of application 

3 for such renewal grant— 

4 ‘‘(1) continues to meet the criteria specified in 

5 subsection (d); and 

6 ‘‘(2) has made demonstrable progress in the de7 velopment of one or more new, self-supporting com8 munity coalitions that are focused on the prevention 

9 and treatment of substance use and misuse. 

10 ‘‘(g) GRANT AMOUNTS.— 

11 ‘‘(1) IN GENERAL.—Subject to paragraphs (2) 

12 and (3), the total amount of grants awarded to a coa13 lition under this section for a fiscal year may not ex14 ceed the amount of non-Federal funds raised by the 

15 coalition, including in-kind contributions, for that 

16 fiscal year. Funds appropriated for the substance use 

17 and misuse activities of a coalition that includes a 

18 representative of the Bureau of Indian Affairs, the In19 dian Health Service, or a tribal government agency 

20 with expertise in the field of substance use prevention 

21 may be counted as non-Federal funds raised by the 

22 coalition. 

23 ‘‘(2) INITIAL GRANTS.—The amount of the ini24 tial grant awarded to a coalition under subsection (a) 

25 may not exceed $75,000. 


pbinns on DSK79D2C42PROD with BILLS
147 

•HR 5925 RH

1 ‘‘(3) RENEWAL GRANTS.—The total amount of 

2 renewal grants awarded to a coalition under sub3 section (f) for any fiscal year may not exceed $75,000. 

4 ‘‘(h) FISCAL YEAR LIMITATION ON AMOUNT AVAIL5 ABLE FOR GRANTS.—The total amount available for grants 

6 under this section, including renewal grants under sub7 section (f), in any fiscal year may not exceed the amount 

8 equal to five percent of the amount authorized to be appro9 priated by section 1038 for that fiscal year. 

10 ‘‘(i) PRIORITY IN AWARDING INITIAL GRANTS.—In 

11 awarding initial grants under this section, priority shall 

12 be given to a coalition that expressly proposes to provide 

13 mentorship to a coalition or aspiring coalition serving eco14 nomically disadvantaged areas. 

15 ‘‘§ 1036. Authorization for National Community Anti16 drug Coalition Institute 

17 ‘‘(a) IN GENERAL.—The Director shall, using amounts 

18 authorized to be appropriated by subsection (d), make a 

19 competitive grant to provide for the continuation of the Na20 tional Community Anti-drug Coalition Institute. 

21 ‘‘(b) ELIGIBLE ORGANIZATIONS.—An organization eli22 gible for the grant under subsection (a) is any national non23 profit organization that represents, provides technical as24 sistance and training to, and has special expertise and 


pbinns on DSK79D2C42PROD with BILLS
148 

•HR 5925 RH

1 broad, national-level experience in community antidrug 

2 coalitions under this subchapter. 

3 ‘‘(c) USE OF GRANT AMOUNT.—The organization that 

4 receives the grant under subsection (a) shall continue a Na5 tional Community Anti-Drug Coalition Institute to— 

6 ‘‘(1) provide education, training, and technical 

7 assistance for coalition leaders and community teams, 

8 with emphasis on the development of coalitions serv9 ing economically disadvantaged areas; 

10 ‘‘(2) develop and disseminate evaluation tools, 

11 mechanisms, and measures to better assess and docu12 ment coalition performance measures and outcomes; 

13 and 

14 ‘‘(3) bridge the gap between research and prac15 tice by translating knowledge from research into prac16 tical information. 

17 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—The Di18 rector shall, using amounts authorized to be appropriated 

19 by section 1038, make a grant of $2,000,000 under sub20 section (a), for each of the fiscal years 2019 through 2023. 

21 ‘‘§ 1037. Definitions 

22 ‘‘In this subchapter: 

23 ‘‘(1) ADMINISTRATOR.—The term ‘Adminis24 trator’ means the Administrator appointed by the Di25 rector under section 1031(c). 


pbinns on DSK79D2C42PROD with BILLS
149 

•HR 5925 RH

1 ‘‘(2) COMMUNITY.—The term ‘community’ shall 

2 have the meaning provided that term by the Adminis3 trator. 

4 ‘‘(3) ELIGIBLE COALITION.—The term ‘eligible 

5 coalition’ means a coalition that meets the applicable 

6 criteria under section 1032(a). 

7 ‘‘(4) GRANT RECIPIENT.—The term ‘grant recipi8 ent’ means the recipient of a grant award under sec9 tion 1032. 

10 ‘‘(5) PROGRAM.—The term ‘Program’ means the 

11 program established under section 1031(a). 

12 ‘‘(6) SUBSTANCE USE AND MISUSE.—The term 

13 ‘substance use and misuse’ means— 

14 ‘‘(A) the illegal use or misuse of drugs, in15 cluding substances for which a listing is in effect 

16 under any of schedules I through V under section 

17 202 of the Controlled Substances Act (21 U.S.C. 

18 812); 

19 ‘‘(B) the misuse of inhalants or over the 

20 counter drugs; or 

21 ‘‘(C) the use of alcohol, tobacco, or other re22 lated product as such use is prohibited by State 

23 or local law. 

24 ‘‘(7) YOUTH.—The term ‘youth’ shall have the 

25 meaning provided that term by the Administrator. 


pbinns on DSK79D2C42PROD with BILLS
150 

•HR 5925 RH

1 ‘‘§ 1038. Drug–free communities reauthorization 

2 ‘‘(a) AUTHORIZATION OF APPROPRIATIONS.—There 

3 are authorized to be appropriated to the Office to carry out 

4 this subchapter $99,000,000 for each of fiscal years 2019 

5 through 2023. 

6 ‘‘(b) ADMINISTRATIVE COSTS.—Not more than 8 per7 cent of the funds appropriated for this subchapter may be 

8 used by the Office or, in the discretion of the Director, an 

9 agency delegated to carry out the program under section 

10 1031(d) to pay for administrative costs associated with car11 rying out the program.’’. 

12 (d) TECHNICAL AND CONFORMING AMENDMENT.—The 

13 table of chapters for subtitle I of title 31, United States 

14 Code, is amended by adding at the end the following new 

15 item: 

‘‘10. Office of National Drug Control ............................................................ 1001’’. 

16 SEC. 3. REPEALS. 

17 The following provisions are repealed: 

18 (1) Section 203 of the Office of National Drug 

19 Control Policy Reauthorization Act of 2006 (Public 

20 Law 109–469; 21 U.S.C. 1708a). 

21 (2) Title VIII of the Office of National Drug 

22 Control Policy Reauthorization Act of 2006 (Public 

23 Law 109–469). 


pbinns on DSK79D2C42PROD with BILLS
151 

•HR 5925 RH

1 (3) Section 1105 of the Office of National Drug 

2 Control Policy Reauthorization Act of 2006 (Public 

3 Law 109–469; 21 U.S.C. 1701 note). 

4 (4) Section 1110 of Office of National Drug Con5 trol Policy Reauthorization Act of 2006 (Public Law 

6 109–469; 21 U.S.C. 1705 note). 

7 (5) Section 1110A of the Office of National Drug 

8 Control Policy Reauthorization Act of 2006 (Public 

9 Law 109–469; 21 U.S.C. 1705 note). 

10 (6) Section 4 of Public Law 107–82 (21 U.S.C. 

11 1521 note). 

12 SEC. 4. OPIOID CRISIS RESPONSE. 

13 (a) EMERGING THREAT DESIGNATION.—The Director 

14 shall designate opioids and opioid analogues as emerging 

15 threats, in accordance with section 1009 of title 31, United 

16 States Code, as added by section 2(b). 

17 (b) OPIOID RESPONSE PLAN.— 

18 (1) ISSUANCE.—Not later than 60 days after the 

19 date of the enactment of this Act, the Director shall 

20 publish, make publicly available, and notify the 

21 President and the appropriate congressional commit22 tees of, the plan required under section 1009 of title 

23 31, United States Code, as added by section 2(b), to 

24 be designated as the ‘‘National Opioid Crisis Re25 sponse Plan’’. 


pbinns on DSK79D2C42PROD with BILLS
152 

•HR 5925 RH

1 (2) CONTENTS.—The Director shall ensure the 

2 plan establishes measurable goals, including reducing 

3 fatal and non-fatal overdoses, and includes the fol4 lowing: 

5 (A) Initiatives to ensure the United States 

6 mail is effectively screened to prevent illicit 

7 drugs from entering the United States, includ8 ing— 

9 (i) designating the United States Post10 al Service as a National Drug Control Pro11 gram Agency; 

12 (ii) directing the United States Postal 

13 Service and any other related National 

14 Drug Control Program Agency to take any 

15 appropriate actions necessary to reduce the 

16 amount of illicit drugs entering the country; 

17 and 

18 (iii) developing an international co19 ordination plan, in accordance with section 

20 1010 of such title 31, United States Code, as 

21 added by section 2(b)), to include efforts to 

22 address international drug control initia23 tives and strengthen bilateral and multilat24 eral strategies to reduce illicit drugs and 

25 precursor chemicals from entering the 


pbinns on DSK79D2C42PROD with BILLS
153 

•HR 5925 RH

1 United States through international mail or 

2 across land borders or ports of entry. 

3 (B) Support for universal adoption of evi4 dence-based prescribing guidelines, including— 

5 (i) establishing a task force to supple6 ment existing prescribing guidelines with 

7 evidence-based standards and to facilitate, 

8 coordinate, and, as appropriate, conduct re9 search to inform such guidelines; 

10 (ii) encouraging the adoption of evi11 dence-based prescribing guidelines by each 

12 relevant agency, State and local govern13 ments, and private sector organizations; 

14 (iii) issuing guidance to National 

15 Drug Control Program Agencies to, as ap16 propriate, revise regulations to ensure pro17 fessionals have effective continuing edu18 cation requirements; and 

19 (iv) disseminating and encouraging the 

20 adoption of best practices and evidence21 based guidelines for effective prescribing 

22 practices. 

23 (C) A program to monitor the prescription 

24 drug market and illicit drug market for changes 


pbinns on DSK79D2C42PROD with BILLS
154 

•HR 5925 RH

1 in trends relevant to reducing the supply or de2 mand of such drugs. 

3 (D) An initiative to facilitate and coordi4 nate Federal, State and local government initia5 tives, studies, and pilot or demonstration pro6 grams designed to evaluate the benefits of drug 

7 courts and related programs that reduce sub8 stance use prevalence. 

9 (E) Programs, developed in coordination 

10 with the private sector, to— 

11 (i) facilitate the development of treat12 ment and deterrent products, in accordance 

13 with section 1010(c) of title 31, United 

14 States Code, as added by section 2(b); and 

15 (ii) encourage the expansion of medica16 tion disposal programs and technology. 

17 (F) Initiatives to encourage the National 

18 Drug Control Program Agencies and the pro19 gram established under section 1010(d) of title 

20 31, United States Code, as added by section 

21 2(b)— 

22 (i) to prioritize the development of sen23 tencing standards or model codes for traf24 ficking opioids and opioid analogues; and 


pbinns on DSK79D2C42PROD with BILLS
155 

•HR 5925 RH

1 (ii) to advise States on establishing 

2 laws and policies to address opioid issues 

3 based on the recommendations developed 

4 and set forth by the President’s Commission 

5 on Combating Drug Addiction and the 

6 Opioid Crisis. 

7 (G) Working groups, established in accord8 ance with section 1010 of title 31, United States 

9 Code, as added by section 2(b), to develop stand10 ards, and encourage the use of such standards, 

11 for the collection of data necessary to understand 

12 and monitor the opioid crisis, including— 

13 (i) State medical examiner reports on 

14 deaths caused by overdoses and related sta15 tistical data; and 

16 (ii) first responder opioid intoxication 

17 incidents. 

18 (H) A program to identify successful college 

19 recovery programs, including sober housing pro20 grams that provide a shared living residence free 

21 of alcohol or illicit drug use for individuals re22 covering from drug or alcohol addiction and sub23 stance use disorders, on college campuses and 

24 disseminate best practices to Colleges and UniVerDate Sep 11 2014 20:53 Jun 20, 2018 Jkt 079200 PO 00000 Frm 00155 Fmt 6652 Sfmt 6203 E:\BILLS\H5925.RH H5925

pbinns on DSK79D2C42PROD with BILLS
156 

•HR 5925 RH

1 versities to increase the number and capacity of 

2 such programs. 

3 (I) Convening working groups, consisting of 

4 the appropriate National Drug Control Program 

5 Agencies, State, local and Tribal governments, 

6 and other appropriate stakeholders, established 

7 in accordance with section 1010 of title 31, 

8 United States Code— 

9 (i) to support Prescription Drug Moni10 toring Programs by— 

11 (I) facilitating the sharing of pro12 gram data among States and Federal 

13 prescription drug monitoring pro14 grams to ensure interoperability of 

15 such programs; 

16 (II) assisting States in increasing 

17 utilization of such programs; 

18 (III) facilitating efforts to incor19 porate available overdose and naloxone 

20 deployment data into such programs; 

21 (IV) evaluating barriers to inte22 grating program data with electronic 

23 health records; and 

24 (V) offering recommendations to 

25 address identified barriers; and 


pbinns on DSK79D2C42PROD with BILLS
157 

•HR 5925 RH

1 (ii) to develop standards, and encour2 age the use of such standards, for the collec3 tion of data necessary to understand and 

4 monitor the opioid crisis, including— 

5 (I) State medical examiner re6 ports on deaths caused by overdoses 

7 and related statistical data; and 

8 (II) first responder opioid intoxi9 cation incidents. 

10 (J) Research initiatives, to be initiated not 

11 later than 30 days after the issuance of the plan, 

12 to evaluate the uses and barriers to use of and 

13 the effects of improving the following programs: 

14 (i) Medication Assisted Treatment. 

15 (ii) Data collection systems used to 

16 confirm opioid use by individuals who have 

17 been arrested or hospitalized. 

18 (K) A requirement for an Advisory Com19 mittee on Substance Use Disorder Treatment 

20 Standards, to be established not later than 120 

21 days after the issuance of the plan, to promul22 gate model evidence-based standards for sub23 stance use disorder treatment and recovery fa24 cilities which— 

25 (i) shall be chaired by the Director; 


pbinns on DSK79D2C42PROD with BILLS
158 

•HR 5925 RH

1 (ii) shall include as members of the ad2 visory committee representatives of the rel3 evant National Drug Control Program 

4 Agencies; 

5 (iii) may include as members of the 

6 advisory committee government regulators, 

7 State representatives, consumer representa8 tives, substance use disorder treatment pro9 viders, recovery residence owners and opera10 tors, and purchasers of substance use dis11 order treatments; and 

12 (iv) shall ensure such model standards 

13 are promulgated no later than 2 years after 

14 the date of the issuance of the plan. 

15 (c) RECOMMENDATIONS.—Not later than 1 year after 

16 the date of the enactment of this Act, the Director shall sub17 mit to Congress a report on the results of the initiatives 

18 conducted under subsection (b)(2)(K) and recommendations 

19 based on such results. 

20 SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION. 

21 (a) RULES OF CONSTRUCTION.—Nothing in this Act, 

22 or the amendments made by this act shall be construed as 

23 derogating the authorities and responsibilities of the Direc24 tor of National Intelligence or the Director of the Central 

25 Intelligence Agency contained in the National Security Act 


pbinns on DSK79D2C42PROD with BILLS
159 

•HR 5925 RH

1 of 1947 (50 U.S.C. 401 et seq.), the Central Intelligence 

2 Agency Act of 1949 (50 U.S.C. 403a et seq.), or any other 

3 law. 

4 (b) INAPPLICABILITY TO CERTAIN PROGRAMS.—This 

5 Act, and the amendments made by this Act, shall not apply 

6 to the National Intelligence Program and the Military In7 telligence Program, unless such program or an element of 

8 such program is designated as a National Drug Control 

9 Program— 

10 (1) by the President; or 

11 (2) jointly by— 

12 (A) in the case of the National Intelligence 

13 Program, the Director and the Director of Na14 tional Intelligence; or 

15 (B) in the case of the Military Intelligence 

16 Program, the Director, the Director of National 

17 Intelligence, and the Secretary of Defense. 

18 (c) CLASSIFIED INFORMATION.—Any contents of any 

19 report required under this Act or the amendments made by 

20 this Act that involve information properly classified under 

21 criteria established by an Executive order shall be presented 

22 to Congress separately from the rest of such report. 

23 SEC. 6. GAO STUDY AND REPORTS. 

24 (a) REPORTS.— 


pbinns on DSK79D2C42PROD with BILLS
160 

•HR 5925 RH

1 (1) INITIAL.—Not later than 3 years after the 

2 date of the enactment of this Act, the Comptroller 

3 General shall provide an initial report to the appro4 priate Congressional Committees. 

5 (2) FINAL.—Not later than 6 years after the date 

6 of the enactment of this Act, the Comptroller General 

7 shall provide a final report to the appropriate Con8 gressional Committees. 

9 (b) CONTENTS OF REPORT.—The reports described in 

10 subsection (a) shall include the following: 

11 (1) A review of the implementation of the edu12 cation and outreach campaign for emerging threats, 

13 including— 

14 (A) whether the objectives of the campaign 

15 and the media campaign have been met during 

16 the relevant period; and 

17 (B) whether the Office took steps to ensure 

18 that the campaign operated in an efficient and 

19 effective manner consistent with the overall strat20 egy and focus of the campaign. 

21 (2) A review of the adherence to policies and 

22 practices implemented to ensure that Federal funds 

23 were used responsibly to purchase advertising time 

24 and space and eliminate the potential for waste, 

25 fraud and abuse. 


pbinns on DSK79D2C42PROD with BILLS
161 

•HR 5925 RH

1 (3) An evaluation of the most recent, applicable 

2 National Drug Control Strategy, including whether 

3 the National Drug Control Strategy met the require4 ments of section 1005 of title 31, United States Code, 

5 as added by section 2(b). 

6 (4) An evaluation of whether the required annual 

7 assessments prepared by the Office met the require8 ments of section 1006 of title 31, United States Code, 

9 as added by section 2(b). 

10 (5) Such other matters as the Comptroller Gen11 eral determines to be appropriate. 

12 SEC. 7. DEFINITIONS. 

13 In this Act, the terms ‘‘appropriate congressional com14 mittees’’, ‘‘Director’’, ‘‘drug’’, ‘‘illicit drug use’’, ‘‘illicit 

15 drugs’’, and ‘‘National Drug Control Program Agencies’’ 

16 have the meaning given those terms in section 1001 of title 

17 31, United States Code. 


pbinns on DSK79D2C42PROD with BILLS
Union Calendar No. 596 

115TH CONGRESS 

2D SESSION H. R. 5925 

[Report No. 115–767, Part I] 

A BILL 

To codify provisions relating to the Office of 

National Drug Control, and for other purposes. 

JUNE 20, 2018 

Reported from the Committee on Oversight and 

Government Reform with an amendment 

JUNE 20, 2018 

The Committees on Energy and Commerce, Foreign AfUnionand ordered to be printed mittee of the Whole House on the State of the and Appropriations discharged; committed to the Com- fairs, the Judiciary, Intelligence (Permanent Select), 


pbinns on DSK79D2C42PROD with BILLS